David James Kerr
CBE, MA (Oxon), MBChB, BSc (Hons), MSc, PhD, MD, DSc, FRCP
(Glasgow,Edinburgh and London), FRCGP (hon), FCanSci, FMedSci
CURRICULUM VITAE
Professor of Cancer Medicine, University of Oxford
Adjunct Professor of Medicine, Weill Cornell Medical College, New York
Past President, European Society of Medical Oncology
1
CONTENTS
EDUCATION .......................................................................................................................... 3
POSTGRADUATE FELLOWSHIPS AND PRIZES ........................................................................... 4
MEDICAL ONCOLOGY CAREER ................................................................................................ 5
CURRENT APPOINTMENTS ..................................................................................................... 5
MEMBERSHIP OF SOCIETIES .................................................................................................. 6
CLINICAL AND SCIENTIFIC LEADERSHIP ................................................................................ 10
CLINICAL DUTIES ................................................................................................................. 10
TRANSLATIONAL CANCER RESEARCH: GENE THERAPY OF CANCER .......................................... 11
INTERACTION WITH INDUSTRY............................................................................................. 13
INTERNATIONAL COLLABORATIONS: ..................................................................................... 13
ORGANISATIONAL LEADERSHIP............................................................................................. 11
RESEARCH GRANTS RECEIVED .............................................................................................. 13
PUBLICATIONS ..................................................................................................................... 19
PUBLISHED ABSTRACTS ........................................................................................................ 19
THESES ................................................................................................................................ 19
PEER REVIEWED PUBLICATIONS............................................................................................ 19
PUBLISHED BOOK CHAPTERS ................................................................................................ 45
EDITED BOOKS..................................................................................................................... 47
JOURNAL EDITORIAL BOARDS ............................................................................................... 47
2
EDUCATION
University of Glasgow
Medical degrees
MBChB
MD
1980
Aspects of Cytotoxic Drug Penetration
1987
Science degrees
BSc
First class honours in Biochemistry
1977
MSc
in Clinical Pharmacology
1990
PhD
Regulation of proliferation of breast cancer cells by growth factors
1990
DSc
The molecular and clinical pharmacology of anticancer therapy
1996
University of Oxford
MA
2002
HONOURS and FELLOWSHIPS
Elected Fellow of Royal College of Physicians and Surgeons, Glasgow (FRCP, Glas)
1995
Elected Fellow of Royal College of Physicians, London
(FRCP, Lon)
1996
Elected Fellow of Academy of Medical Sciences
(FMed Sci)
2000
Awarded Commander of Order of British Empire, by HM the Queen
(CBE)
2002
Elected Honorary Fellow of Royal College of General Practitioners
(FRCGP)
2007
Elected Founding Fellow of European Academy of Cancer Sciences
(FCanSci)
2009
Elected Fellow of Royal College of Physicians, Edinburgh
(FRCP, Edin)
2010
3
POSTGRADUATE FELLOWSHIPS AND PRIZES
Graham Wilson Travelling Fellow
1985
Jean M MacKintosh Research Fellowship
1985
Visiting Scientist, Chronobiology Laboratories, University of Minnesota, Minneapolis, USA
1986
Cancer Research Campaign Travel Fellowship
1986
Graham Wilson Travelling Fellow
1986
Travelling Fellowship from National Cancer Institute to attend laboratories of Dr M Lippman
and Dr M Sporn
1987
Travelling Fellowship Royal College of Physicians and Surgeons, Glasgow
1987
Alexander Fletcher Memorial Prize, Royal College of Physicians and Surgeons for distinguished
research into thyroid cancer
1987
European School of Oncology International Award for outstanding contribution to
chemotherapy research
1987
Graham Wilson Travelling Fellow, University of Glasgow
1988
British Association for Cancer Research Fellowship
1988
International Union against Cancer - Cancer Research Fellowship International Cancer
Research Exchange Technology Transfer Grant
1989
May and Baker Prize for essay on Aspects of Therapy Royal College of Physicians & Surgeons,
Glasgow
1991
Pauline TSU Memorial Lecture, Royal College of Physicians & Surgeons, Edinburgh
1992
International Society of Geriatrics - Zeneca Lecture "Treatment of cancer in the elderly"
1995
Royal Society of Art Annual Lecture
1995
10th Erasmus Darwin Lecture
1996
2 International Prize for Excellence in the field of Colorectal Cancer Research and
Treatment – Awarded by International Drug Development Centre and European
Association for Research into Gastrointestinal Cancer
nd
1999
1st Nye Bevan Award for Innovation – Awarded by NHS for Gene Therapy Research
2000
AstraZeneca: Oncology and Infections Vision and Values Award
2005
Distinguished Medeval Lecture, University of Manchester
2006
European Society of Medical Oncology Award for distinguished contribution to
Cancer therapy and research in Europe
2006
Fulton Lecture, University of Glasgow
2007
Bruce Cain Memorial Lecture, Cancer Societies of Australia and New Zealand
2008
4
MEDICAL ONCOLOGY CAREER
University of Glasgow
Prof S B Kaye CRC Dept of Medical Oncology,
CRC Research Fellow (Honorary Registrar)
April 1984 - September 1986
Beatson Institute for Cancer Research,
Honorary Senior Registrar
MRC Recombinant DNA Training Fellowship
October 1986 - September
1988
CRC Senior
Registrar
Senior
October 1988 - June 1989
CRC Senior Fellow, Senior Lecturer in Medical
Oncology and Honorary Consultant Physician
and Pharmacology Group Leader
CRC Dept of Medical Oncology,
July 1989 - February 1992
Honorary Professor of Pharmacology, University
of Strathclyde
July 1990 – present
Research
Fellow,
Hon
University of Birmingham
Professor of Clinical Oncology and Clinical
Director,
CRC Institute for Cancer Studies,
March 1992 – 2001
Honorary Consultant Physician,
Oncology Centre,
Queen Elizabeth and City Hospitals
March 1992 – 2001
Birmingham
University of Oxford
Director, National Translational Cancer Research
Network
October 2001 – April 2006
Rhodes Professor of Cancer Therapeutics and
Clinical Pharmacology;
October 2001 – March 2009
Head of Department Clinical Pharmacology;
Fellow, Corpus Christi College , Oxford;
Honorary Consultant in Medical Oncology Radcliffe Hospital Trusts
5
Sidra Medical and Research Centre, Doha,
Qatar (leave of absence from Oxford)

Chief Research Advisor

Member, Supreme Health Council, State of
Qatar

Professor of Cancer Medicine, University of
Oxford

Adjunct Professor of Medicine, Weill Cornell
Medical College

Honorary Consultant in Medical Oncology –
Al Amal Hospital, Doha
March 2009 – October 2010
October, 2010 - current
Professor of Cancer Medicine,
Nuffield Dept of Clinical and
Sciences, 2010 - present
Laboratory
Seconded as Health Adviser to Sec State for
Health ,UK October, 2010 – August, 2012
Adjunct Professor of Medicine, Weill Cornell
Medical College, 2009 - present
President, European Soc Medical Oncology,
2009 – 11
Chief
Medical
officer,
Biomarkers, 2011 - present
Oxford
Cancer
MEMBERSHIP OF SOCIETIES
 British Oncology Association
 British Association for Cancer Research
 European Society of Medical Oncology
 Association of Cancer Physicians
6
 European Association for Cancer Research
 American Association for Cancer Research
 American Society for Clinical Oncology
7
MEMBERSHIP OF EXECUTIVE COMMITTEES
Local
 University of Oxford
▪
Committee of Heads of Departments of Science, 2001-2009
▪
Committee of Heads of Departments of Medical School, 2001-2009
▪
Chair, Biomedical Sciences Prize Committee, 2005-2009
▪
Central Committee for Estates (representing Division of Medicine), 2006-2009
National
 Medical Research Council, Molecular and Cell Medicine Board, Committee A, Member (1993-1997)
 Medical Research Council, Colorectal Cancer Working Party, Member - responsible for coordinating two international trials in advanced colorectal cancer. (1992-2003)
 Medical Research Council, Clinical Fellowships Panel. (1993-1996)
 Medical Research Council, Realising Our Potential Awards Committee.(1995-1996)
 Medical Research Council, LINK with Industry Panel. (1995)
 Advisory Group to Commission for Health Improvement (1998)
 Cancer Research Campaign, Clinical Trials Committee, Member (1998-2001)
 Chairman, National Cancer services Collaborative (budget £30 million). (1999 – 2003)
 Chairman and Clinical Lead, Department of Health Audit on Cancer Waiting Times. (1999)
 Founding Commissioner, Commission for Health Improvement.(1999-2001)
 Cancer Research Campaign, Site Visit Committee member and responsibility for grant reports.
 Adviser, Commonwealth Scholarships and Fellowships (1999 – present)
 National Cancer Task Force, Member. (2000 – 9)
 Director of National Translational Cancer Research Network (2001- 2006)
 Chairman National Cancer Research Institute’s adjuvant colorectal cancer trials group (2003 – 8)
 Member, National Colorectal Cancer Advisory Group (2003 – present)
 Member, Department of Health Research for Patient Benefits Working Party (2003- 2005)
 Chairman, National Framework for NHS in Scotland: Advisory Group (2004 – 2005)
8
International
 Pan European Trial of Adjuvant Chemotherapy for Colorectal Cancer – Trial Steering Committee,
UK Chairman (1995-1998)
 European Society for Medical Oncology, Chairman of Scientific Committee - responsible for
arranging and ensuring a high scientific content of ESMO Athens meetings (1998)
 American Society for Clinical Oncology - international liaison committee of senior European and
American oncologists linking ESMO and ASCO meetings (1998)
 International Working Party on Colorectal Cancer: this group consists of senior academics from
USA and each European Country with an interest in the treatment of colorectal cancer.(1999)
 EORTC, Gastro-intestinal Study Group, Member - responsible for trans-European studies in a
range of gastro-intestinal cancer. (1998 – present)
 Editor-in-Chief, Annals of Oncology; scientific journal of European Society of Medical Oncology
and Europe's leading clinical cancer journal. (1999 – present)
 US National Institute of Health Colorectal Cancer Research Strategy Group – overseas member,
2000
 Co-Chairman, Scientific Steering Committee for centenary celebration of Entente Cordiale –
“Today’s Science, Tomorrow’s Patient” 2003 – 2005)
 US National Cancer Institute – Translational Research Working Group (sole overseas member)
2005-2007
 European Society of Medical Oncology, Presidential Cycle, 2008-2014
 Chairman of INDOX – www.indox.org.uk – 2005 to date
 Chairman of AfrOx – www.afrox.org – 2007 – to date
 Member of International Scientific Advisory Board for Center for Translational
Molecular Medicine, The Netherlands – 2008 (present distribution of 500 million
Euros)
 Member of International Assessment Committee for Research Hospital Fund of
Canadian Foundation for Innovation: distribution of $500 million, 2008
 Member of Advisory Board of the Centre for Cancer Biomedicine, The Norwegian
Radium Hospital, Norway, 2008 - date.
 Member of Scientific Advisory Board of Institut Gustav Roussy, Paris (2009- to date)
 Supreme Council of Health, Qatar (2009 – 10)
 Chairman, OxOnics – Asia-Pacific Oncology development company (2011 – present)
9
CLINICAL AND SCIENTIFIC LEADERSHIP
Working in partnership with Professor Alan Rickinson FRS. I established the CRC Institute for Cancer
Studies in University of Birmingham, built the scientific establishment from around 50-60 staff to 150200 and secured funding to construct a new laboratory to house the expanded workforce. I
supported construction of a new cancer hospital in Birmingham, forged a series of innovative clinical
practices, founded clinical gene therapy in Birmingham and spun out a small biotech company,
COBRA Therapeutics.
Appointment to the Rhodes Chair of Cancer Therapeutics and Clinical Pharmacology (October, 2001),
University of Oxford has allowed me to work with Sir John Bell to build a new Institute for Cancer
Medicine in Oxford, (£60 million) contiguous with the new cancer hospital (£125 million) on the
Churchill Biomedical Campus. My recent appointed as Chief Research Advisor to the Sidra Medical
and Research Centre ($3 billion build and design project) has allowed me to share the vision of Her
Highness Sheikha Mozah in her desire to build a world class research environment in Doha. This
represented an extraordinary opportunity to develop a world-class research centre with a particular
emphasis on translating findings from basic science into novel diagnostic or therapeutic agents for
patients who suffers from chronic disease burden of Qatar (cancer, diabetes and cardiovascular
disease).I have returned to Oxford as Professor of Cancer Medicine, Radcliffe Dept of medicine and
Chief medical Officer of Oxford Cancer Biomarker
This work was recognised by award of CBE (2002) by HM the Queen.
CLINICAL DUTIES and COLORECTAL CANCER RESEARCH
In Oxford I have joined the multidisciplinary gastro-intestinal cancer team, established a contract
with the Danish Government to see and treat their refractory liver cancer patients, developed a
gastrointestinal cancer study group within my Clinical Trials Unit and have accrued large patient
numbers to local, national and international studies. Richard Gray and I ran QUASAR, a trial of
adjuvant chemotherapy in colorectal cancer which successfully recruited 8500 patients in 8 years
making it one of the largest and therefore potentially most influential cancer trials in the world. This
has continued in Oxford with VICTOR, a placebo-controlled study of a selective COX-2 inhibitor,
rofecoxib in an adjuvant setting for CRC which has recruited 2,500 patients. QUASAR 2 (3,750
patients) will compare standard chemotherapy versus Capecitabine and Bevacizumab, a regime which
was developed in our own unit. This work has established the UK and my Unit as international
leaders in the field of treatment and research into colorectal cancer. More recently, we have
extended this work through collaboration with Prof Ian Tomlinson into the field of Genome Wide
Association studies, with some notable success. I joined the Al Amal Hospital in Doha as Consultant
Medical Oncologist and have been charged by Her Highness Sheikha Mozah with developing a cancer
plan for the Nation.
Contribution to the field of colorectal cancer research and treatment was recognised in
1999 by the award of the 2nd International GI Cancer prize by the Institute for Drug
Development and European Association for Research into Gastrointestinal Cancer and the
ESMO award, 2006.
10
TRANSLATIONAL CANCER RESEARCH
I have been involved in cancer drug development for 30 years and established a phase I Trials Unit in
the University of Birmingham, working later with Professor Lawrence Young to develop an MRCfunded virus-based gene therapy programme. I joined the Oxford Cancer Centre experimental trials
group working with consultant colleagues, Prof Mark Middleton and Professor Adrian Harris with
approximately 200-300 patients referred per annum for consideration of novel therapy with signal
transduction inhibitors from the Pharma industry and our own account gene therapy programme
(preclinical lead is Professor Len Seymour). I have conducted approximately 30 phase 1 trials.
Contribution to the field of gene therapy was recognised by award of the NHS’ first Nye
Bevan award for Research Excellence.
ORGANISATIONAL LEADERSHIP
Academic (Universities of Birmingham and Oxford): As documented previously, I played a
significant role in partnership with Alan Rickinson FRS, in establishing the CRC Institute for Cancer
Studies in Birmingham and leading its development to one of the largest and best funded academic
departments in the University of Birmingham. I was asked to do the same in Oxford, working closely
with Sir John Bell, with a vision of constructing a comprehensive cancer centre which will be ranked
amongst the top 10 in the world within 15 years of its inauguration. We have secured funding from
the Department of Health for a new cancer hospital (£125 million) and have raised £60 million for the
new laboratory. Importantly, in a time of increasing academic compartmentalisation, I established a
series of collaborations across different divisions (Biomedical Engineering, Chemistry, Said Business
School, Mathematics and Computer Science).
National Translational Cancer Research Network (NTRAC):
I was commissioned by Secretary of State for Health to devise a costed blue print for provision of
infrastructure to support clinical cancer research in the UK (NCRN and NTRAC). This was accepted
and funded (£100 million) as part of the National Cancer Plan and I was subsequently appointed
Director of NTRAC. This was a fascinating challenge, working with the best cancer research centres in
the UK to forge them into a collaborative network, greater than the sum of its component points.
International recognition of NTRAC’s ground breaking work has come in the form of invitations to;
establish jointly funded translational science research fellowships between NTRAC and the NCI
Washington and the French government’s Canceropoles; develop a European wide plan (ETRAC) to
construct a Network of its top comprehensive cancer centres, along very similar lines to NTRAC;
shape the Danish government’s plan to fund early clinical trial centres; provide intellectual
underpinning for the US National Cancer Tissue Bank.
NTRAC served as a ground breaking blue
print for the other Department of Health innovations in forming research networks for cardiovascular
disease, diabetes, mental health etc.
National Health Service, UK: Under the auspices of Brian Edwards, Chief Executive of West
Midlands Regional Health Authority, I assembled a cancer services task force, developed a delivery
strategy, and led the Regional team in its implementation over a 4 year period (1993-1997). This
involved writing a Cancer Plan defining the relevant standards and the evidence base supporting
these. The “hub and spoke” Network model which we elected to use has been developed further
and incorporated into the National Cancer Plan, and we boiled the predicant philosophy down to four
key elements:

Site specialisation by cancer surgeons and oncologists


Multidisciplinary working
Development of regional treatment guidelines (often precursor of national guidelines)
11

Use of IT as a social glue to bind the Network together.
This led to national investment in Cancer Services and fed forward into improving our National
cancer survival figures and governmental investment of £670 million.
Department of Health: There are three National Programmes which I have led on behalf of the
DH which have involved taking a strategic overview, finding effective solutions to complex problems
and initiating cultural change in the NHS:
National Audit of Cancer Waiting Times (1999): I delivered the first set of comprehensive data
on cancer waiting times across the entire health service in England. This information was presented
to ministers and was so profoundly disturbing, given the length of delays, that it was one of the
dominant strands which resulted in creation of a National Cancer Plan - British Medical Journal 320,
838-839.
Founding Commissioner For Health Improvement (1999-2001): I was invited to become a
founding Commissioner stemming from an earlier piece of work in which I supported the main
committee established to define CHI’s roles and responsibilities. I chaired the first review of the
National Service Framework on Cancer Services, performed jointly with the Audit Commission (CHIAudit Commission report on Cancer Services, 2000) its publication helped to highlight those areas of
the cancer plan which were most vulnerable so that appropriate action might be taken and celebrate
the obvious successes. Perhaps most importantly, we wrote this document so that it would be
accessible to the lay reader and published a series of questions (in collaboration with the Guardian
and Mirror) that patients could pose to their medical teams to ensure that they were getting optimal
care.
Cancer Services Collaborative (1999-2003): Seeing the need to reform the mode of delivery of
cancer services, Helen Bevan (Director of Redesign, NHS Institute) and I secured funding to work
with Don Berwick (Institute for Health Improvement, Boston) to create the Cancer Services
Collaborative, the largest health care redesign programme ever undertaken. Results are detailed on
web site (http://www.modern.nhs.uk), but in summary, significant gains were made in waiting times
across the cancer patient’s journey, a much larger proportion of cancer patients were discussed by
multidisciplinary teams and the quality of available patient information was greatly enhanced. This
involved engagement with an initially sceptical clinical community and delivery of a complex National
programme. The Cancer Services Collaborative involved expenditure of £30 million over 3 years, a
staff of approximately 300 facilitators, managers and clinicians, which at its peak was reporting 1000
change episodes per month. We gained unique insights into large scale change management, the
important elements of evincing clinical engagement, the problems associated with spread and
sustainability of new practice and how we could use innovative communication practice to build a
modernisation movement.
National Framework for Service Change in NHS Scotland (2004-2005): I was invited by
Scotland’s First Minister to chair the work of a National Framework Advisory Group to consider the
future shape of the NHS in Scotland. We produced three volumes of work, “Building a Health Service
Fit for the Future” (Vol I and II) and a web-based data link showing the Reports from the individual
action teams (www.show.scot.nhs.uk/national framework). The eponymous Kerr Report received
strong support from citizens, health care professionals, unions (BMA and RCN), media and cross-party
parliamentary endorsement. It has been adopted as the blueprint for Scotland’s NHS over the next
20 years.
Sidra Medical and Research Centre (2009-2010): I was employed by Her Highness Sheikha
Mozah, Consort of the Emir of Qatar to build the Research Division of the Sidra Medical and Research
Centre, supported by the largest hospital endowment in the world ($9 billion) and an annual research
budget rising to $200 million per annum. I practiced medicine at the local cancer hospital, Al Amal,
and have been appointed to the Supreme Council of Health, effectively the Qatar’s Health Cabinet,
and have been asked to support development of a National Health Plan. This position has allowed me
to develop links with the wider world of Islam through the Organisation of the Islamic Conference
(OIC), and I have been invited to build a Translational Research Network of the OIC’s top biomedical
research Institutes.
12
Health Adviser to David Cameron and Conservative Party (2010-12 )
I have supported the intellectual underpinning of the Health White Paper and provided a clinical
Advisory role to David Cameron, Andrew Lansley and Conservative party.
INTERACTION WITH INDUSTRY
I have established board level links with a number of global pharmaceutical and healthcare
companies which has led to significant grant funding eg Glaxo Smith Kline (£3 million), Merck (£14
million), Roche (£6.5 million) GE Healthcare (£2 million) and AstraZeneca (£1 million). I was part of
the Drug Development Team which won Astra Zeneca’s Oncology and Infections Visions and Values
prize in 2005.
Oxford has an impressive record of protecting and developing its IPR and establishing spin out
companies. When working in the University of Birmingham, I established one of their first
biotechnology spin outs, a gene therapy company, COBRA Therapeutics. In Oxford, I have worked
with ISIS to construct a cancer drug development company, Celleron and Oxford Cancer Biomarkers a
platform technology-based biotech company which identifies chemotherapy sensitivity biomarkers.
INTERNATIONAL COLLABORATIONS:
USA
I sit on NIH’s Translational Research working group as the overseas member and
have established a series of collaborations with the USA’s major cancer research
centres (Mayo Clinic, MD Anderson, Memorial Sloan Kettering and Dana Farber,
Harvard).
INDIA
having attracted grant funding from the pharmaceutical company GSK, we have
constructed a network of India’s top 10 cancer centres, in partnership with
Oxford.
This collaboration will provide training opportunities for Indian
investigators in Oxford and will build an internationally competitive clinical
research network (www.indox.org.uk).
EUROPE
I had the opportunity to co-chair the Entente Cordiale Celebrations on behalf of
HM the Queen and President Chirac, 2003-2005. As President of ESMO (20102012) I am in a strong position to improve standing of Medical Oncology in
Europe and sit on the Dutch government’s central committee for translational
research with a budget of 1 billion Euros.
AFRICA
I have established a consortium comprising the International Atomic Energy
Agency, International Agency for Cancer Research, and the Union Internationals
Contre Le Cancer to develop cancer control programmes in Sub Saharan Africa
and created AfrOx (www.afrox.org) the vehicle to implement change.
FAR EAST
I have established OxOnics, a drug development company with my colleague Dr
Wenn Sun. It has a mission to bring novel anti-cancer agents to the Asia-pacific
rim with a focus on China.
13
RESEARCH GRANTS RECEIVED
1989

Health Board Research Support Group - £10,000.
One year's salary for Research Assistant.

EEC (European against cancer initiative) - £230,000 over two years
as part of an international collaborative group chaired by Prof S S Davis, Dept. Pharmacy,
University of Nottingham

Cancer Research Campaign Project Grant - £160,000.
3 years' salary - clinical research fellow & post doctoral scientist for research into use of
Mitomycin C microcapsules by intrahepatic arterial administration in hepatic metastatic
carcinoma.
Grant Holders - D Kerr, C McArdle, A Whately.
1990

Scottish Hospital Endowment Research Trust- £44,000
2 year's salary for research assistant - molecular biology of breast cancer

Cancer Research Campaign - £80,000 over 3 years
Joint project with Dr I Pragnell, Beatson Institute for Cancer Research, funding a clinical
research fellow to investigate preclinical toxicology of marrow stem cell inhibitor
1991

Scottish Hospital Endowment Research Trust - £75,000
3 year salary for senior post-doctoral scientist for project on population pharmacokinetics of
cytotoxic drugs in breast cancer therapy

Cancer Research Campaign - £200,000 per annum
Supervision of programme grant expenditure of CRC Pharmacology Group - 5 year
programme Grant.
1992

Scottish Hospital Endowments Research Trust - £50,000
2 year's salary for senior post-doctoral scientist for project on formulation of cytotoxic drugs
for cerebral implantation in the treatment of brain tumours.
Grant Holders - D J Kerr, T A Whately, R Rampling, J Plumb

Queen Elizabeth Endowment Trust - £42,000
Development of Inhibitors of P-Glycoprotein.
Grant Holders - D J Kerr, D R Ferry

Queen Elizabeth Endowment Trust - £27,000
Interaction of Platinum with the HIV Promoter Sequence.
Grant Holders - D J Kerr, C J Poole, L Young

Cancer Research Campaign - £500,000
14
Laboratory Refurbishment grant on joining University of Birmingham
Grant Holder – D J Kerr

Cancer Research Campaign - £620,000
Molecular Pharmacology Group
Grant Holder – D J Kerr

Cancer Research Campaign - £1 million
Programme Grant Supporting Clinical Trials Unit
Grant Holder – D J Kerr
1994

Regional Health Authority- £5 million
To house the expanding Institute for Cancer Studies
Grant holder - D J Kerr
September 1995-September 1999

Medical Research Council £1,501,304
Gene Therapy of Common Cancers: Immunological & Pharmacological Approaches to
Gynaecological Cancer.
Grant holders - LS Young, PF Searle, D. Luesley, AB Rickinson, PH. Gallimore

Cancer Research Campaign £1.25 million
Departments Expenses-Core Funding 1995-1999
Grant holders - AB Rickinson and DJ Kerr
September 1994-September 1997

Glaxo Research and Development Limited (plc) - £75,000
A Co-administration of rising oral GG918 Dose Levels with Doxorubicin Phase 1 Study
Grant holders - DJ Kerr
January 1995-January 1998

M.L. Laboratories plc - £75,794
Adjuvant Intraperitoneal Chemotherapy with 5-fluorouracil in Duke’s Stage B and C Colic
Adenocarcinoma (VICTOR)
Grant holder - DJ Kerr
November 1995-November 1997

Special Trustees of the Former UBH Trust £49,233
Investigation of Phospholipase Signal Transduction Pathways in Human Breast Cancer
Grant holders - DJ Kerr and MJO Wakelam
March 1997-March 1998

Takeda Chemical Industries Ltd. (Japan) £42,000
A Phase II Open Label Study to Determine the Safety Tolerability and Efficacy of
CV6504(HCI) in Patients with pancreatic cancer
Grant holders - DJ Kerr
September 1996-September 1999

Glaxo-Wellcome R and D £120,000
15
Immunological and Pharmacological Aspects of Gene Therapy
Grant holders - DJ Kerr
1996-2001

Cancer Research Campaign £616,335
Core Clinical Fellowships
Grant holders - DJ Kerr
1997-2001

Cancer Research Campaign £1,102,030
Clinical Trials Unit – Core Support
Grant holders - DJ Kerr
1995-1998

Cancer Research Campaign £68,526
West Midlands Trials of Adjuvant Treatment in Early Breast Cancer
Grant holder - DJ Kerr
1998-2003

Cancer Research Campaign £534,695
Pre-Clinical and Clinical Pharmacology and Macromolecular Drug Targeting
Grant holder - DJ Kerr
1998-2002

Cancer Research Campaign £135,690
ATTOM UKCCCR Randomised Trial to Establish Optimum Length of Adjuvant Tamoxifen
Grant holder - DJ Kerr
1994-1997

Ministry of Agriculture, Fisheries and Food £200,742
Evaluation of Non-Nutrient Dietary Constituents in Prevention of Breast Cancer
Grant holders - DJ Kerr, A Gescher, K. Chipman
1997

The Higher Education Funding Council Capital £249,640
Research and Development for a Boron Cancer Therapy Clinical Facility
Grant holders - DJ Kerr, N James, D. Beynon
1996-2001

NHS Research and Development Office £2.2 million
Foundation of a Regional Clinical Trials Unit
Grant holders - DJ Kerr, R Hobbs, L Ward, J Dunn, J Kenkre
1994-1999
 Medical Research Council £1.36 million
QUASAR Adjuvant Trial of Colorectal Cancer Chemotherapy
Grant holders - DJ Kerr and R Gray
16
1998

Wellcome Trust £2.8 million
Construction of a clinical research facility
Grant holders – M Sheppard, P Stewart, DJ Kerr, M Wakelam, LS Young, AB Rickinson, C
Savage
1998-2003

Medical Research Council £403,608
Co-operative Group – Translational Research: Gene and Immunotherapy of Cancer.
Grant holders: DJ Kerr, DH Adams, PAH Moss, V Mautner, PF Searle, L Seymour and LS
Young

Medical Research Council £68,240
Joint Research Equipment Initiative Award
Grant Holders: P Moss, A Rickinson, D Kerr, J Gordon, L Young C Bunce
1997-2002

Zeneca Pharmaceuticals £1,130,000
Clinical Trials Grant for Adjuvant Colorectal Cancer Trial: PETACC

Medical Research Council £600,000
FOCUS : trial of chemotherapy in advanced colorectal cancer
Grant Holders: M Seymour, R James, D J Kerr, T Maugham and R Stephens
17
Recently awarded grants
MERCK – Cancer Research Campaign £12.6 million – 2002 – 2009
Trial of adjuvant therapy with cyclooxygenase inhibitors in colorectal cancer
Grant Holder: D J Kerr
Roche/Aventis – Cancer Research Campaign £4 million – 2004 - 2009
Adjuvant trial of chemotherapy for colorectal cancer
Grant Holder: D J Kerr
Genomic Healthcare £83,330 - 2006-2008
Proteomic investigation of colorectal cancer
Grant holder: D J Kerr
NHS R & D £20 million - 2001 – 2006
To establish the National Translational Cancer Research Network (NTRAC) and the National Cancer
Tissue Resource (NCTR).
Grant Holder: D J Kerr
E-Science Pilot Project in Integrative Biology - £ 1,244 310
Lead investigator: D Gavaghan
Co-investigator: D J Kerr
CRUK Gene Therapy Programme Grant - £1.2 million - 2004 - 2009
Lead investigator: L Seymour
Co-investigator: D J Kerr
Genomic and proteomic approaches to identify novel Markers of Colorectal Cancer, MRC Co-operative
Grant:
£215,788 – 2004 -2007
Lead investigators: D J Kerr and I Tomlinson
GE Healthcare: Molecular Basis of Colorectal Cancer - £2.4 million – 2005-2007
Lead Investigator: D J Kerr
Cancer Research UK, Research Grant, ECMC Award - CRUK funding for the experimental cancer
medicine centre - £3,070,410 - 2007 – 2012
Lead investigator: A Harris
Co-investigator: D J Kerr
EUROCAN: £80,421- 2005 – 2007
Lead investigator: P Boyle
Co-investigator: D J Kerr
SCOT Study ad adjuvant colorectal cancer chemotherapy: MRC £1,798,433 – 2006- 2014
Lead investigator: J Cassidy
Co-investigator: D J Kerr
Roche Ltd: £1.5 million – 2012 – current
Lead Investigator: DJ Kerr
Oxford Cancer Biomarkers: £3.25 million – 2011- current
18
PUBLICATIONS
PUBLISHED ABSTRACTS
Over 300 Abstracts presented at national and international conferences.
THESES
BSc:
Degradation of the neuropeptide, metenkephalin by human plasma
MSc
The clinical pharmacology of LM985 - an experimental cytotoxic drug
MD
Aspects of cytotoxic drug penetration
PhD
Regulation of proliferation of breast cancer cells by growth factors.
DSc
The Molecular pharmacology of anticancer therapy
PEER REVIEWED PUBLICATIONS
In 4 sections: Colorectal Cancer; Drug Development; Gene Therapy; General Medicine
Section 1: Colorectal Cancer
Huijbers A, Tollenaar RAEM, Pelt GWV, Zeestraten ECM, Dutton S, McConkey CC, Domingo E, Smit
VTHBM, Midgley R, Warren BF and Kerr DJ
The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients:
Validation in the victor trial
Annals of Oncology 24(1):179-185 2013
Domingo E, Ramamoorthy R, Oukrif D, Rosmarin D, Presz M, Wang H, Pulker H, Lockstone H, Hveem
T, Cranston T, Danielsen H, Novelli M, Davidson B, Xu ZZ, Molloy P, Johnstone E, Holmes C, Midgley
R, Kerr D, Sieber O, Tomlinson IUse of multivariate analysis to suggest a new molecular classification
of colorectal cancer. J Pathol 229(3):441-448 Feb 2013
Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Almeida EG,
Salguero I, Sherborne A, Chubb D, Carvajal-Carmona LG, Ma Y, Kaur K, Dobbins S, Barclay E,
Gorman M, Martin L, Kovac MB, Humphray S, The CORGI Consortium, Thomas HJ, Maher E, Evans G,
Lucassen A, Cummings C, Stevens M, Walker L, Halliday D, Armstrong R, Paterson J, Hodgson S,
Homfray T, Side L, Izatt L, Donaldson A, Tomkins S, Morrison P, Goodman S, Brewer C, Henderson A,
Davidson R, Murday V, Cook J, Haites N, Bishop T, Sheridan E, Green A, Marks C, Carpenter S,
Broughton M, Greenhalge L, Suri M, The WGS500 Consortium, Steering Committee:, Donnelly P, Bell
J, Bentley D, McVean G, Ratcliffe P, Taylor J, Wilkie A, Operations Committee:, Donnelly P, Broxholme
J, Buck D, Cazier JB, Cornall R, Gregory L, Knight J, Lunter G, McVean G, Taylor J, Tomlinson I, Wilkie
19
A, Sequencing & Experimental Follow-up:, Buck D, Gregory L, Humphray S, Kingsbury Z, Data
Analysis:, McVean G, Donnelly P, Cazier JB, Broxholme J, Grocock R, Hatton E, Holmes CC, Hughes L,
Humburg P, Kanapin A, Lunter G, Murray L, Rimmer A, Lucassen A, Holmes CC, Bentley D, Donnelly
P, Taylor J, Petridis C, Roylance R, Sawyer EJ, Kerr DJ, Clark S, Grimes J, Kearsey SE, Thomas HJ,
McVean G, Houlston RS, Tomlinson I Germline mutations affecting the proofreading domains of POLE
and POLD1 predispose to colorectal adenomas and carcinomas.
Nat Genet 45(2):136-144 23 Dec 2012
Beggs AD, Domingo E, McGregor M, Presz M, Johnstone E, Midgley R, Kerr D, Oukrif D, Novelli M,
Abulafi M, Hodgson SV, Fadhil W, Ilyas M, Tomlinson IP Loss of expression of the double strand break
repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70
expression is associated with CIN.
Oncotarget 3(11):1348-1355 Nov 2012
Schmoll HJ, Van cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, Van de
Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D,
Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky
G, Douillard JY, El ghazaly H, Gallardo J, Garin A, Glynne-jones R, Jordan K, Meshcheryakov A,
Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A Esmo consensus guidelines for
management of patients with colon and rectal cancer. A personalized approach to clinical decision
making Annals of Oncology 23(10):2479-2516 2012
Kennedy RH, Francis A, Dutton S, Love S, Pearson S, Blazeby JM, Quirke P, Franks PJ, Kerr DJ
EnROL: A multicentre randomised trial of conventional versus laparoscopic surgery for colorectal
cancer within an enhanced recovery programme
BMC Cancer 12 2012
Kinnersley B, Migliorini G, Broderick P, Whiffin N, Dobbins SE, Casey G, Hopper J, Sieber O, Lipton L,
Kerr DJ, Dunlop MG, Tomlinson IP, Houlston RS The TERT variant rs2736100 is associated with
colorectal cancer risk
British Journal of Cancer 107(6):1001-1008 2012
La Thangue, NB and Kerr DJ. Predictive biomarkers: a shift towards personalised cancer medicine
Nature Reviews Clinical Oncology 8, 587-596,.2011
Kerr,DJ and Young AM. Targeted therapies:Bevacizumab – has it reached its final resting place?
Nature Reviews Clinical Oncology 8, 195-196 , 2011
J Hecht, T Trarbach, J Hainsworth, P Major, E Jager, R Wolff, K Lloyd-Salvant, G Bodoky, K
Pendergrass, W Berg, B Chen, T Jalava, G Meinhardt, D Laurent, D Lebwohl, and D Kerr. A
Randomized, Placebo-Controlled, Phase III Study of First-line Oxaliplatin-Based Chemotherapy Plus
PTK787/ZK 222584 (Vatalanib), an Oral VEGF Receptor Inhibitor, in Patients With Metastatic
Colorectal Adenocarcinoma J Clin Oncol, 2011:1997-2003
Niedzwiecki D, Bertagnolli M, Warren S, Compton CC, Kemeny NE, Benson AB, Eckhardt SG, Alberts
SR, Porjosh GN , Kerr DJ, Fields, Goldberg< Mayer R, Colaccio TA Documenting the natural historyof
20
patients with resection of stage2 adenocarcinoma of the colon after randomisation to Edrocolomab or
observation. . J Clin Oncol , 11, 2011:3146-3152
Quirke P, Hutchins G, Southward K, Hardley K, Magill L, Beaumont C, Stahlschmidt J, Rickman S,
Chambers P, Seymour M, Gray R and Kerr DJ. Value of mismatch repair, KRAS and BRAF mutations
in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol,
2011:1261-1270
Salazar R, Roepman P, Capella G, Moreno V, Simon I, López-Doriga1 A, Marijnen C, Westerga J,
Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Van Velthuysen L, M Glas A, Van ’t Veer L
and Tollenaar R. A Gene Expression Signature to Improve Prognosis Prediction of Stage II and III
Colorectal Cancer J Clin Oncol, 1,2011:17-24
Gray R, Quirke P, Hardley K, Lopatin M, Magill L, aehner FL, Beaumont C, Clark-Langore KM,
Yoshiwarza CN, Lee M, Watson D, Shak S and Kerr DJ. Validation Study of a Quantitative multi-gene
RT-PCR assay as a predictor of recurrence in stage II colon cancer patient. J Clin Oncol,
12,2011:4611-4619
Houlston R, Cheadle J, Dobbins S, et al. Meta-analysis of three UK genome-wide association studies
identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nature
Genetics, 42,973-77,2010.
Chen l, Zeng X, Wang J, Briggs SS, O’Neil E, Li J, Leek R, Kerr DJ, Harris AL, Cai L . Roles of
Tetrahydrobiopterin in promoting tumour angiogenesis. Am J Pathol 2010 , 179: 2671-2680
Midgley RS, McConkey C, Kerr DJ et al. Final Results of the VICTOR Trial: A Phase III Randomized
Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer. J Clin Oncol, 4575-4580,
2010.
Kerr DK and Midgley R. Defective Mismatch Repair in Colon Cancer: A prognostic or predictive
biomarker? – Journal of Clinical Oncology, 3210-3212, 2010
The International Cancer Genome Consortium. Sequencing the cancer genome.
Nature 2010 Apr
15;464(7291):993-8.
Kerr SH, Kerr DJ. Novel treatments for hepatocellular cancer. Cancer Letters 286 (2009) 114–120
Al-Salama H, Johnstone E and Kerr DJ. What Is the Role and Impact of Molecular Markers on
Treatment Decisions for Colorectal Cancer in the Adjuvant Setting? Discovery Medicine. 2009.
Discovery Medicine, volume 8, number 42, Pages 104-107.
Kerr DJ and Kakil IR. Targeted therapies: Cetuximab plus chemotherapy in patients with advanced
cancer. Nature Reviews Clinical Oncology. 2009 Sep;6(9):499-500
Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr DJ. Genetic prognostic and
predictive markers in colorectal cancer. Nature Reviews Cancer, 2009, 9: 489-499.
Luis S, Spain S, Tomlinson I, Kerr D; Houlston R, Cazier J. Common variation at the Adiponectin locus
is not associated with colorectal cancer risk in the United Kingdom. Human Molecular Genetics,
18, 1889-1892, 2008.
Midgley RS, Yanagisawa Y, Kerr DJ. Evolution of nonsurgical therapy for colorectal cancer. Nat Clin
Pract Gastroenterol Hepatol. 2009 Feb;6(2):108-20.
Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R,
O’Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, De Gramont A, for the Adjuvant
21
Colon Cancer Endpoints (ACCENT) Group16. Evidence for cure by adjuvant therapy in colon cancer:
Observations Based on Individual Patient Data from 20,898 Patients of 18 Randomized Trials. : J Clin
Oncol. 2009 Feb 20;27(6):872-7.
Midgley R, Kerr DJ. Capecitabine: have we got the right dose? Nature Clinical Practice. Vol 6: 1,
17-24. Oct 2008.
Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven N, Kerr DJ, Young LS,
Adams DH. 3A Phase II Study of Adoptive Immunotherapy Using Dendritic Cells Pulsed with Tumor
Lysate in Patients with Hepatocellular Carcinoma. Hepatology. 2009 Jan;49(1):124-32.
Popov I, Carrato A, Sobrero A, Vincent M, Kerr D, Labianca R, Raffaele Bianco A, El-Serafi M,
Bedenne L, Paillot B, Minik, Evaristo E. Raltitrexed (Tomudex_) versus standard leucovorinmodulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in
Adjuvant Colon Cancer 01 (PETACC-1). 2008. European Journal of Cancer, 44, 2004-2211.
Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset J-F, Cunningham D, De Gramont A, DiazRubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang YK, Kerr D, Labianca R, Minsky BD,
Moore M, Nordlinger B, Rougier R, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, Tempero M,
Van De Velde C, Zalcberg J. The diagnosis and management of rectal cancer. Expert discussion
and recommendations derived from the 9th world congress on gastrointestinal cancer, Barcelona,
2007. Annals of Oncology. 19 (supplement 6): vii1-vi8, 2008
Kerr DJ. Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as
first-line treatment. Nature Clinical Practice Oncology. Vol 5, 250-251.2008
Cogent Study Group Meta-analysis of genome-wide association data identifies four new susceptibility
loci for colorectal cancer. Nat Genetics 40, 1426-35,2008
Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman A, Spain S , Lubbe S,
Walther A, Sullivan K, Jaeger E, Fielding S, Rowan A, Vijayakrishnan J, Domingo E, Chandler I,
Kemp Z, Qureshi M, Farrington S, Tenesa A, Prendergast J, Barnetson R, Penegar S, Barclay E, Wood
W, Martin L, Gorman M, Thomas H, Peto J, Bishop T, Gray R, Maher E, Lucassen A, Kerr D, Evans E,
The CORGI Consortium, Schafmayer C, Buch S, Izke H, Hampe J, Schreiber S, John U, Koessler T,
Pharoah P, van Wezel T, Morreau H, Wijnen J, Hopper J, Southey M, Giles G, Severi G, Castellvı´-Bel
S, Ruiz-Ponte C, Carracedo A, Castells A, The EPICOLON Consortium, Fo¨rsti A, Hemminki K,
Vodicka P, Naccarati A, Lipton L, WC Ho J, Cheng K, Sham P, Luk J, Agu´ ndez J , Ladero J, de la
Hoya M, Calde´s T, Niittyma¨ki I, Tuupanene S, Karhu A, Aaltonen L, CazierJB, Campbell H, Dunlop
M, & Houlston R. A genome-wide association study identifies novel colorectal cancer susceptibility
loci on chromosomes 10p14 and 8q23.3. Nature Genetics.
40, 623-630. 2008.
Jaeger E, Webb E, Howart K, Carvajal-Carmona L, Rowan A, Broderick P, Walther A, Spain S, Pittma
A, Kemp Z, Sullivan K, Heinimann K, Lubbe, Domingo E, Barclay E, Martin L, Gorman M, Chandler I,
Vijayakrishna J, Wood, Papaemmanuil E, Penegar S, Qureshi M, members of the CORGI consortium,
Tenesa A, Cazier JB, Kerr D, Gray R, Peto P, Dunlop M, Thomas HH, Houlston R, Tomlinson I.
Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal
cancer risk. Nature Genetics, 40: 26-28, 2007.
Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A, Lubbe S, Spain S,
Sullivan K, Fielding S, Jaeger E, Vijayakrishnan J, Kemp Z, Gorman M, Chandler I, Papaemmanuil E,
Penegar S, Wood W, Sellick G, Qureshi M, Teixeira A, Domingo E, Barclay E, Martin L, Sieber O, Kerr
D, Gray R, Peto J, Cazier JP, Tomlinson I, Houlston R. A genome-wide association study shows that
22
common alleles of : SMAD7: influence colorectal cancer risk. Nature Genetics 39, 1315 - 1317 (14
Oct 2007).
Sabharwal A and Kerr D. Chemotherapy for colorectal cancer in the metastatic and adjuvant setting:
past, present and future. Expert Review Anticancer Therapy. 7 (4), 477-487, 2007.
Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D,
Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore
M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll H, Tabernero J, Tempero M,
Van De Velde C, Van Laethem JL, Zalcberg J. The management of pancreatic cancer. Current expert
opinion and recommendations derived from the 8th world congress on gastrointestinal cancer,
Barcelona, 2006. Annals of Oncology. 18 (supplement 7): vii1-vii10, 2007.
Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Francois Seitz
J, O'callaghan CJ, Francini G, Grothey A, O'connell M, Catalano PJ, Kerr D, Green E, Wieand HS,
Goldberg RM, Gramont AD. End Points for Colon Cancer Adjuvant Trials: Observations and
Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18
Randomized Trials From the ACCENT Group. J Clin Oncol. 29: 4569-4574, 2007.
Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, Penegar S, Chandler I,
Gorman M, Wood W, Barclay E, Lubbe S, Martin L, Sellick G, Jaeger E, Hubner R, Wild R, Rowan A,
Fielding S, Howarth K, Silver A, Atkin W, Muir K, Logan R, Kerr D, Johnstone E, Sieber O, Gray R,
Thomas H, Peto J, Cazier JB, Houlston R. A genome-wide association scan of tag SNPs identifies a
susceptibility variant for colorectal cancer at 8q24.21. Nature Genetics 39, 984-988 (01 Aug 07)
Kerr DJ, Dunn JA, Langman MD, Smith JL, Midgley RJ, Stanley A, Stokes JC, Julier P, Iveson C,
Duvvuri R, McConkey CC. Rofecoxib and Cardiovascular adverse events in adjuvant treatment of
colorectal cancer. New England Journal of Medicine, 357:360-9. July 2007
Gray, R, Barnwell J, McConkey C, Williams N and Kerr, DJ. QUASAR: a randomised study of adjuvant
chemotherapy versus observation including 3239 colorectal cancer patients QUASAR Collaborative
Group. Lancet, 370(9604):2020-9. 2007
Kerr David J. Does chemotherapy given directly to the liver improve survival in patients with hepatic
metastasis? Nature Clinical Practice Oncology 3, 480 – 481. 2006.
Shimizu, Maruta F, Akita N, Miwa S, Seymour L, Kerr, D, Parker A, Miyagawa S. Identification of an
oligopeptide binding to Hepatocellular carcinoma. Oncology 941. 2006
Russo, A, Bazan V, Iacopetta B, Kerr, D, Sonssi T, Gebbia N. The TP53 Colorectal Cancer
International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation:
Influence of Tumour Site, Type of Mutation, and Adjuvant Treatment. Journal of Clinical
Oncology. 23: 2005, 7518-7528.
Sargent DJ, Wieand HS, Haller D G, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O’Callaghan
CJ, Francini G, Grothey A, O’Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre
T, Goldberg RM, De Gramont A. Disease-free survival versus overall survival as a primary end point
of adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomised
trials. Journal of Clinical Oncology. 2005, 23, No 34: pp. 8664-8670
Rea DW, Nortier JW, Ten Bokkel Huinink WW, Falk S, Richel DJ, Maughan T, Groenewegen G, Smit
JM, Steven N, Bakker JM, Semiond D, Kerr DJ, Punt CJ. A phase I/II and pharmacokinetic study of
irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann
Oncol. 2005 Jul;16(7):1123-32. Epub 2005 Jun 6.
23
Neoptolemos J. P., Stocken D. D., Friess H., Bassi C., Dunn J. A., Hickey H., Beger H., FernandezCruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D. J., Büchler M.
W. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
New England Journal of Medicine. 350; 12. March 2004.
Chan, R and Kerr DJ. Can we individualise chemotherapy for colorectal cancer? Annals of Oncology.
15, 996-999, July 2004
Kerr D and Van Cutsem E. New approaches for the treatment of colorectal cancer in the adjuvant
setting. Eur J Cancer. Vol 2 No 7, 34-39. 2004
Grabsch H, Kerr D and Quirke P. Is there a case for routine clinical application of ploidy
measurements in gastrointestinal tumours?. Histopathology. 45, 312-334. 2004
Kerr D. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nature Clinical
Practice, Oncology. Vol 1, 39-43, 2004
Kerr DJ. Clinical development of gene therapy for colorectal cancer.
(2003) 3 615-622.
Nature Reviews Cancer,
Grumett, SA and Kerr DJ. Irinotecan and Capecitabine in a patient with advanced colorectal cancer.
Case Studies in Colorectal Cancer. (August 2003), Vol2, No.5.
Nicum S, Midgley R, Kerr DJ. Colorectal cancer. Acta Oncol. 2003;42(4):263-75.
Kerr, D.J., McArdle, C.S; Ledermann, J; Taylor, I; Sherlock, S.J; Schlag, P.M; Buckels, J; Mayer, D;
Cain, D; Stephens, R.J. Intrahepatic arterial versus intravenous 5 fluorouracil and leucovorin for
colorectal cancer liver metastases: results of a multicentre randomised trial, Lancet, 2003, 361,368373
Midgley, RS; Kerr, D.J. Immunotherapy for colorectal cancer. Expert Rev. Anticancer Ther. 3(1),
63-78, 2003.
Maughan TS, James RD, Kerr D, Ledermann JA, Seymour MT, Topham C, McArdle C, Cain D,
Stephens RJ on behalf of the MRC Colorectal Cancer Group Comparison of intermittent and
continuous palliative chemotherapy for advanced colorectal: a multicentre randomized trial. Lancet,
2003;361:457-64
Hosie KB, Kerr DJ, Gilbert JA, Downes M, Lakin G, Pemberton G, Timms K, Young A and Stanley A. A
Pilot study of adjuvant intraperitoneal 5-fluororuarcil using 4% icodextrin as a novel carrier solution.
European Journal of Surgical Oncology. (2003) 29: 254-260
Pendlebury S, Duchesne F, Reed K, Smith JL and Kerr DJ. A trial of adjuvant therapy in colorectal
cancer: The VICTOR Trial. Clinical Colorectal Cancer. (2003) Vol 3:1. 58-60
Van Cutsem E, Dicato M, Wils J, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Johnston P, Kerr
D, Koehne CH, Labianca R, Minsky B, Nordlinger B, Roth A, Rougier P and Schmoll HP. Adjuvant
treatment of colorectal cancer (current expert opinion derived from the Third International
Conference: Perspectives in Colorectal Cancer, Dublin 2001) European Journal of Cancer. 2002,
38, 1429-1436.
Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, Cohen D, Hopwood P,
Johnston C, Stephens RJ. Comparison of survival, palliation, and quality of life with three
chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002,
359, 1555-1563
24
Midgley RS, Kerr DJ (2002) Ras as a target in Cancer Therapy. Critical Reviews in Haematology
and Oncology 44(2):109-120
Tebutt NC, Cattell E, Midgley RS, Cunningham D, Kerr DJ. (2002) Systemic therapy of colorectal
cancer. Eur.J.Oncol. 38(7): 1000-1015
Nicum S, Midgley RS, Kerr DJ (2002) Chemotherapy and Radiotherapy for Colorectal Cancer.
In:Recent Advances in Coloproctology-Volume 2. In press
Kerr, D.J.,and Midgley, R.S. (2002). Immunotherapy for colorectal cancer: potential application in an
adjuvant setting. Semin Oncol 27, 132-7.
Hussain, S.A., Ferry, D.R., El-Gazzas, G., Mirza, D.F., James, N.D., McMaster, P., and Kerr, D.J.
(2001). Hepatocellular carcinoma. Ann Oncol 12, 161-72.
Kerr DJ. A United Kingdom Coordinating Committee on Cancer Research Study of Adjuvant
Chemotherapy for Colorectal Cancer: Preliminary Results. Seminars in Oncology, 28(1): 31-34
(2001)
Hosie K, Gilbert JA, Kerr D, Brown CB, Peers EM. Fluid Dynamics in Man of an Intraperitoneal Drug
Delivery Solution: 4% Icodextrin. Drug Delivery, 8: 9-12 (2001).
Neoptolemos JP, Dunn JA, Moffitt DD, Almond J, Link K, Beger H, Bassi C, Pederzoli P, Dervenis C,
Fernandez-Cruz L, Lacaine F, Spooner D*, Kerr DJ*, Friess H, Buchler M. European Study Group for
Pancreatic Cancer-1 interim results: a European randomized study to assess the roles of adjuvant
chemotherapy and chemoradiation in resectable pancreatic cancer. British Journal of Surgery
2001;88(3):475Neoptolemos, J.P; Dunn,J.A; Stocken,D.D; Almond,J; Link,K; Beger,H; Bassi,C; Falconi,M; Pederzoli,P;
Dervenis,C; Fernandez-Cruz,L; Lacaine,F; Pap,A; Spooner,D; Kerr,D.J; Friess,H; Buchler,M.W.
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised
controlled trial. European-Study-Group-for-Pancreatic-Cancer. Lancet. 2001 Nov 10; 358(9293):
1576-85
Snow,P.B; Kerr,D.J; Brandt,J.M; Rodvold, D.M Neural network and regression predictions of 5-year
survival after colon carcinoma treatment. Cancer. 2001 Apr 15; 91: 1673-8
Grumett,S.A; Archer,V.R; Midgley,R; Mulholland,P; Nicum,S; Blewitt,L; Kerr,D.J.
The role of
mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracilfolinic acid chemotherapy. Ann-Oncol. 2001 Apr; 12(4): 575
Kerr, D.J. Two cultures or two faces? Ann-Oncol. 2001 Jan; 12(1): 7-8
Young,A.M; Kerr,D.J. Home delivery: chemotherapy and pizza? British Medical Journal. 2001 Apr
7; 322(7290): 809-10
Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised
trials. Lancet. 2001; 358:1291-1304
Gray RG, Kerr DJ, McConkey CC, et al. On behalf of QUASAR Collaborative Group. Comparison of
fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for
colorectal cancer: a randomised trial. The Lancet, 355, 1588-96 (2000)
25
Midgley RS, Kerr DJ. Towards post-genomic investigation of colorectal cancer. Lancet, Feb 26; 355
(9205): 669-70 (2000)
Sobrero A, Kerr D, Glimelius B, Van Cutsem E, Milano G, Pritchard DM, Rougier P, Aapro M. New
directions in the treatment of colorectal cancer: a look to the future. European Journal of Cancer,
36, 559-566 (2000)
Nicum S, Midgley RS, Kerr DJ. Chemotherapy of colorectal cancer. Journal of the Royal Society
of Medicine, 93, 416-419 (2000)
Midgley, R, Kerr D. Immunotherapy for colorectal cancer: a challenge to clinical trial design. The
Lancet, 159-168 (2000)
Chung-Faye, G.A.,and Kerr, D.J. (2000). ABC of colorectal cancer: Innovative treatment for colon
cancer. British Medical Journal 321, 1397-9.
Midgley, R.S. and Kerr, D.J. (2000). ABC of colorectal cancer: adjuvant therapy. British Medical
Journal 321, 1208-11.
Kerr DJ, Gray R, McConkey C, Barnwell J. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid
and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus fourweekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group. Annals of
Oncology 2000;11(8):947-955
Kerr, D.J., Midgley, R.J., and McArdle, C.S. (2000). Hepatic arterial chemotherapy; Still on trial.
Journal of Clinical Oncology 18, 1806-1807.
Kerr, D.J. (1999). Cost of treating colorectal cancers. European Journal of Cancer 35, 187.
Midgley R, Kerr D, Seminar on Colorectal Cancer. Lancet Vol. 353: 391-99 (1999)
Koehne CH, Midgley R, Seymour M, Kerr DJ. Advanced colorectal cancer: which regimes should we
recommend? Annals of Oncology Aug; 10(8):877-82 (1999)
Ingleby, S., Barnwell, J., Baker, J.,Harvey, P., kerr, D.J., Law, V., and Young, A. (1999). A pilot study
of a feasibility and economic analysis of home based chemotherapy in advanced colorectal cancer.
European Journal of Cancer 35, 214.
Jessop, J.M., Snow, P., Brandt, J., Bellucco, C., Menck, H.R., and Kerr, D.J. (1999). Artificial neural
network prediction of 5-year survival from colon cancer. European Journal of Cancer 35, 211.
Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, Kerr D, Young LS.
Molecular Evolution of the Metaplasia-Dysplasia-Adenocarcinoma sequence in the esophagus.
American Journal of Pathology Vol. 154 (4) (1999)
Langman MJS, Dunn JA, Whiting JL, Burton A, Hallissey MT, Fielding JWL, Kerr DJ. Prospective,
double-blind, placebo-controlled randomised trial of cimetidine in gastric cancer. British Journal of
Cancer, 81(8), 1356-1362 (1999)
Howell JD, Warren HW, Anderson JH, Kerr DJ, and McArdle CS. Intra-arterial 5-fluorouracil and
intravenous folinic acid in the treatment of liver metastases from colorectal cancer. European
Journal of Surgery 1999; Vol 165.652-8.
26
Young AM, Kerr DJ Novel Treatments for Colorectal Cancer, Oncology Today – 1999 18-26
Young AM, Daryanani S, and Kerr DJ. Can pharmacokinetic monitoring improve clinical use of
fluorouracil? Clinical Pharmacokinetics 1999; 36.391-8.
Ingleby, S., Baker, J., Young, A., and Kerr, D.J. (1999). Health economics analysis of home based vs.
hospital based chemotherapy: Discussion of results. British Journal of Cancer 80, 332.
Kerr, D. (1999). Safety of Raltitrexed. Lancet 354, 1825.
Kerr DJ, Ferry DR, Novel therapeutic strategies for colorectal cancer. Hospital Medicine, Vol. 59,
No. 8: 617-621, (1998)
Cocconi G, Cunningham, D, Van Cutsem E, Francois E, Gustavsson B, van Hasal G, Kerr D, Possinger
K, Hietschold SM. Open, randomized , multicenter trial of raltitrexed versus fluorouracil plus high-dose
leucovorin in patients with advanced colorectal cancer. J. Clin. Onc. 16, 9 : 2943-2952, (1998)
Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non-haematological toxicity after 5fluorouracil and leucovorin in patients with advanced colorectal cancer is signjificantly associated with
gender, increasing age and cycle number. Tomudex International Study Group. European Journal
of Cancer, 34 (12): 1871-5 (1998)
Wils J, Sahmoud T, Sobrero A, Bleiberg H, Ahmedzai S, Blazeby J, Blijham G, Conroy T, Cunningham
D, Curran D, Diaz-Rubio E, Ducreux M, Evans J, Glimelius B, Hutchinson G, Kerr D et al. Evaluation of
clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop
organised by the EORTC GITCCG. European Organisation for Research and Treatment of Cancer.
Gastrointestinal Tract Cancer Cooperative Group. Tumori 1998; 84.335-47.
Baker, J., Bleiberg, H., Hutchison, G., Jackman, A., Kerr, D., Labianca, R., Macdonald, J., Meyer, H.J.,
Minsky, B., Nordlinger, B., Rougier, P., Smits, S., Sobrero, A., Taylor, I., and Verweijm J. An
international multidisciplinary approach to the management of advanced colorectal cancer (First of
two parts) (Reprinted from Eur J Surg Oncol, Vol 23, Suppl A, August 1997) Annales Chirurgiae Et
Gynaecologiae 87, 255-264. (1998).
Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A,
Lynch K, Rasmussen H, Kerr D, Cox D, Miller A. Combined Analysis of studies of the effects of the
matrix metalloprote4inase inhibitor marimastat on serum tumor markers in advanced cancer:
selection of a biologically active and tolerable dose for longer-term studies. Clinical Cancer
Research. Vol. 4: 1101-1109, May 1998
Seymour LW, Olliff SP, Poole CJ, de Takats PG, Orme R, Ferry DR, Maeda H, Konno T, Kerr DJ. A
novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate) –
neocarzinostatin] in the treatment of primary hepatocellular carcinoma. International Journal of
Oncology 12: 1217-12223, (1998).
Rougier P, Ducreux M, Kerr D, Carr BI, Francois E, Adenis E and Seymour LA Phase II study of
raltitrexed ‘Tomudex’ in patients with hepatocellular carcinoma. Annals of Oncology 8: 500-502
(1997)
Kerr DJ, O’Connor K.M. The costs of managing advanced colorectal cancer: a broad perspective.
Anti-Cancer Drugs Vol. 8, Suppl 2 1997 S23 (1997)
27
Neoptolemos JP, Kerr DJ, Beger H, Link K, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L,
Laçaine F, Freiss H, Büchler M. ESPAC-1 Trial Progress Report. The European randomised adjuvant
study comparing radiochemotherapy, six months chemotherapy and combination therapy versus
observation in pancreatic cancer. Digestion: 56: 570-577 (1997)
Midgley RS, Kerr DJ. Adjuvant Therapy of Colorectal Cancer. Cancer Treatment Reviews 23:135152. (1997)
Blesing, CH, Julyan, PJ, Barnwell, JM, Parker, DJ, Mountford, PJ, Kerr, DJ, and Harding LK
Quantitative whole body counter distribution studies of 18f-5 fluorouracil following hepatic arterial
and IV infusion. Br. J. Radiology, 32, 14-19 (1996)
Blesing, CH; Kerr, DJ. Intra-hepatic arterial drug delivery. J Drug Targeting 3: 341-347 (1996)
Green, NK, Searle, PF, Young, LS, Kerr, DJ and Neoptolamos JP Gene Therapy for gastrointestinal
cancer, GI Cancer, 2, 43-53 (1996)
De Takats, PG and Kerr DJ Is intra-arterial chemotherapy worthwile in the treatment of patients with
unresectable hepatic colorectal cancer metastases? Eur.J.Cancer 32 13, 2195-2205 (1996)
Kerr, DJ, Young, AM, Neoptolamos, JP, Sherman, J, Van-Geere, P, Stanley, A, Ferry, D, Dobbie, JW,
Vincke, B, Gilbert, J, Dombros, N, and Fountzilos, G.. Prolonged Introperitoneal infusion of 5-FU using
a novel carrier solution. Brit. J. Cancer, 74, 2032-2035 (1996)
McArdle, CS; Anderson, JH; Warren, H; Doughty, J; Kerr, DJ. Intra-arterial 5-FU modulated by folinic
acid for colorectal liver mets.Regional Cancer Treat. 9: 27-29 (1996)
Kerr, DJ. Tomudex ZD 1694, a new direct and specific thymidylate synthase inhibitor, has resource
saving implications in the management of colorectal cancer. Quality of Life Research 4 6: 576
(1995)
Kerr, DJ; de Takats, PG Chemotherapy for gastrointestinal cancer: teaching old drugs new tricks. GI
Cancer 1: 3-7 (1995)
Kerr, DJ; Ledermann, JA; McArdle, CS; Buckels, J; Neoptolemos, J; Seymour, M; Doughty, J; Budden,
J; Taylor, I. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial
fluorouracil. J Clin Oncol 1312: 2968-2972 (1995)
Kerr, DJ; Rustin, GJ; Kaye, SB; Selby, P; Bleehen, NM; Harper, P; Brampton, MH.Phase II trials of
rhizoxin in advanced ovarian, colorectal and renal cancer. Br J Cancer 72: 1267-1269 (1995)
Cunningham, D; Zalcberg, JR; Rath, U; Olver, I; Van Cutsem, E; Svensson, C; Seitz, JF; Harper, P;
Kerr, D; Perez-Mango, G; Azab, M; Seymour, L; Lowery, K & the ‘Tomudex’ Colorectal Cancer Study
Group Tomudex ZD1694: Results of a randomised trial in advanced colorectal cancer demonstrate
efficacy and reduced mucositis and leucopenia. Eur J Cancer 31A 12: 1945-1954 (1995)
Jodrell, DI; Oster, W; Kerr, DJ; Canney, PA; Yosef, H; Steward, WP; Kaye, SB; Cassidy, J. A phase
I/II study of N-phosphonacetyl-L-Aspartic Acid PALA added to 5-Fluorouracil and folinic acid in
advanced colorectal cancer. Eur J Cancer 30a 7: 950-954 (1994)
de Takats, PG; Kerr, DJ; Poole, CJ; Warren, HW; McArdle, CS. Hepatic arterial chemotherapy for
metastatic colorectal carcinoma.Br J Cancer 69: 372-378 (1994)
McArdle, CS; Kerr, DJ; O’Gorman, P; Wotherspoon, HA; Warren, H; Watson, D; Vinke, BJ; Dobbie,
JW; El Eini, DID. Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term
28
intraperitoneal treatment approach for advanced colorectal carcinoma.
766(1994)
Br J Cancer 70: 762-
Warren, HW; Anderson, JH; O’Gorman, P; Kane, E; Kerr, DJ; Cooke, TG; McArdle, CS. A phase II
study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases.
Br J Cancer 70: 677-680 (1994)
Warren, HW; Anderson, JH; O'Gorman, P; Kerr, DJ; Cooke, TG; McArdle, CS. Ambulatory infusion
pumps for intrahepatic arterial chemotherapy. Regional Cancer Treat 2: 77-78 (1993)
McArdle, CS. Glass yttrium-90 microspheres for patients with colorectal liver metastases. Anderson,
JH; Goldberg, JA; Bessent, RG; Kerr, DJ; McKillop, JH, Stewart, I; Cooke, TG; Radiotherapy and
Oncology 25: 137-139. 1992
Anderson, JH; Kerr, DJ; Cooke, TG; McArdle, CS. A phase I study of regional 5-Fluoruracil and
systemic folinic acid for patients with colorectal liver metastases. Br J Cancer 65: 913-915. 1992
Anderson, JH; Kerr, DJ; Setanoians, A; Cooke, TG; McArdle, CS. A pharmacokinetic comparison of
intravenous versus intra-arterial folinic acid.Br J Cancer 65: 133-135. 1992
Kaye, SB; Brampton, M; Harper, P; Smyth, J; Kerr, DJ; Gore, M; Green, JA; Gilby, E; Crawford, SM;
Rustin, GJ. Phase II trials of fosquidone, GR63178A in colorectal, renal and non-small cell lung
cancer. Br J Cancer 65: 624-625. 1992
Kerr, DJ 5-fluorouracil and folinic acid - interesting biochemistry or effective treatment?Brit J Cancer
60 6: 807-809. 1989
29
Section 2: Drug Development and Pharmacology
Khan O, La Thangue, Kerr et al. "HR23B is a biomarker for tumour sensitivity to HDAC inhibitorbased therapy." Proc Nat Acad Science –107(14):6532-7. 2010.
Rahman N M, Davies HE, Salzberg M, Truog P, Midgely R, Kerr D, Clelland C, Hedley EL, Lee YCG,
Davies RJO. Use of lipoteichoic acid-T for pleurodesis in malignant pleural eff usion: a phase I toxicity
and dose-escalation study. Lancet Oncology. 2008. 1016/S1470-2045(08)70205-5.
Middleton M, Knox C, Cattell E, Opperman U, Ali R, Auton T, Agarwal R, Anderson D, Sarker D,
Judson I, Osawa T, Harlley J and Kerr DJ. Quinone Oxido-reductase-2-mediated Prodrug Cancer
Therapy. Science Translational Medicine, 2, 420-428, 2010
Edwards AM, Bountra C, Kerr DJ, Willson TM. Open access chemical and clinical probes to support
drug discovery. Nat Chem Biol. 2009 Jul;5(7):436-40
Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C,
Calver H, Lind M, Robbins A, Burtles S, Duncan R and Cassidy J. Phase II studies of polymerdoxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. International
Journal of Oncology. 2009 Jun;34(6):1629-36.
Midgley R, Kerr D, Flaherty K, Stevenson JP, Pratap S, Koch K, Smith D, Versola M, Fleming R, Ward
C, O'Dwyer P and Middleton M. A phase I and pharmacokinetic study of lapatinib in combination with
infusional 5-fluorouracil, leucovorin and irinotecan. Annals of Oncology 2007 18(12):2025-2029.
Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, Duvauchelle T. Single-dose
clinical pharmacokinetic studies of gefitinib. Clinical Pharmacokinetics. 2005;44(11):1165-77
Kerr DJ, La Thangue N. Signal transduction blockade and cancer : combination therapy or multitargeted inhibitors? Annals of Oncology, 15: 1727-1729, 2004
Danson S, Ferry D, Alkhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G and Ranson M.
Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C)
in patients with advanced cancer. British Journal of Cancer. 2085-2091,2004
Knox RJ, Burke PJ, Chen S, Kerr DJ. CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr
Pharm Des. 2003;9(26):2091-104.
Milner AE, Palmer DH, Hodgkin EA, Eliopoulos AG, Knox PG, Poole CJ, Kerr DJ, Young LS. Induction of
apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with
death receptor ligands in ovarian carcinoma cells. Cell Death Differ 2002;9(3):287-300
Seymour, L.W., Ferry, D.R., Anderson, D., Doran,J, Young, A.M., Kerr, D.J., Hesselwood,S., Julyan,
P.J., Poyner, R. and Burtles, S., Hepatic drug targeting: Phase I evaluation of polymer-bound
doxorubicin J-Clin-Oncol. 2002 Mar 15; 20(6): 1668-76
Taylor,-P-M; Woodfield,-R-J; Hodgkin,-M-N; Pettitt,-T-R; Martin,-A; Kerr,-D-J; Wakelam,M.J. Breast
cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5lipoxygenase catalyzed pathway. Oncogene. 2002 Aug 22; 21(37): 5765-72
30
Mulholland PJ, Ferry DR, Anderson D, Hussain SA, Young AM, Cook JE, Hodgkin E, Seymour LW, Kerr
DJ. Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Annals of
Oncology 2001;12(2):245-248
Ferry DR, Deakin M, Baddeley J, Daryanani S, Bramhall S, Anderson DA, Wakelam MJO, Doran J,
Pemberton G, Young AM, Buckels J & Kerr DJ. A phase II study of the 5-lipoxygenase inhibitor,
CV6504, in advanced pancreatic cancer: Correlation of clinical data with pharmacokinetic and
pharmacodynamic endpoints. Annals of Oncology, 11, 1165-1170 (2000).
Julyan PJ, Seymour LW, Ferry DR, Daryani S, Boivin CM, Doran J, David M, Anderson D,
Christodoulou C, Young AM, Hesslewood S and Kerr DJ. Preliminary clinical study of the distribution
of HPMA copolymers bearing doxorubicin and galactosamine. Journal of Controlled Release
1999; 57.281-90.
Anderson, D., Ferry, D.R., Knox,R.J., Andrews, S.J., Downes, A.J., Kerr, D.J., and Seymour, L.W.
(1999). High-performance chromatographic method for sensitive determination of the alkylating
agent CB1954 in human plasma. Journal of Chromatography B 731, 293-298.
Harper, A., Kerr, D.J., Gescher, A., and Chipman, J.K. (1999). Antioxidant effects of isofavonoids and
lignans, and protection against DNA oxidation. Free Radical Research 31, 149-160.
Harper A, Kerr DJ, Gescher A and Chipman JK. Antioxidant effects of isoflavonoids and lignans, and
protection against DNA oxidation. Free Radical Res., 31, 149-160 (1999)
Murray LS, Jodrell DI, Morrison JG, Cook A, Kerr DJ, Whiting B, Kaye SB, Cassidy J. The effect of
Cimetidine on the pharmacokinetics of Epirubicin in patients with advanced breast cancer: preliminary
evidence of a potentially common drug interaction. Clinical Oncology 10:35-38 (1998)
Helsby NA, Chipman JK, Gescher A and Kerr DJ. Inhibition of mouse and human CYP 1A-and 2E1dependent substrate metabolism by the isoflavonoids Genistein and Equol. Food and Chemical
Toxicology, 36, 375-382 (1998)
Schultze-Mosgau M, Dale IL, Gant TW, Chipman JK, Kerr DJ and Gescher A. Regulation of c-fos
transcription by chemopreventive isoflavonoids and lignans in MDA-MB-468 breast cancer cells.
Europ. J. Cancer,Vol 34 : 9, 1425-1431 (1998)
Helsby NA, Chipman JK, Gescher A and Kerr D. Inhibition of carcinogen-activating cytochrome P450s
by potential chemopreventative agents genistein and equol. Food Chem. Toxicol. 36, 568-577
Christodoulou CV, Eliopoulos AG, Young LS, Hodgkins L, Ferry DR and Kerr DJ. Anti-proliferative
activity and mechanism of action of titanocene dichloride. British Journal of Cancer 77(12: 20882097 (1998)
Christodoulou CV, Ferry DR, Fyfe DW, Young A, Doran J, Sheehan TMT, Elipoulos A, Hale K,
Baumgart J, Sass G, Kerr David J. Phase I Trial of weekly scheduling and pharmacokinetics of
titanocene dichloride in patients with advanced cancer. J. Clin. Oncol 16: 8 2761-2769 (1998)
Julyan PJ, Seymour LW, Ferry DR, Daryani S, Boivin CM, Doran J, David M, Anderson D,
Christodoulou C, Young AM, Hesslewood S Kerr DJ. Preliminary clinical study of the distribution of
HPMA copolymers bearing doxorubicin and galactosamine. Journal of Controlled Release 57: 281290 (1998)
31
Anderson, D; Kerr, DJ; Blesing, C; Seymour, LW Simultaneous gas chromatographic-mass
spectrophotometric determination of a-fluoro-b-alanine and 5-fluorouracil in plasma. J Chromatogr.
688, 87-93 (1997)
Helsby NA, Williams, J, Kerr, D, Gescher, A, Chipman, JK. The isoflavones equol and genistein do not
induce xenobiotic-metabolising enzymes in mouse and in human cells.Xenobiotica, Vol. 27, 6: 587596 (1997)
Cross MJ, Hodgkin MN, Plumb JA, Brunton VG, Stewart A, MacAully G, Hill R, Kerr DJ, Workman P,
Wakelam MJO. Inhibition of phospholipid signalling and proliferation of Swiss 3T3 cells by the
wortmannin analogue demethoxyviridin. Biochimica et Biophysica ACT 1362 29-38 (1997)
Helsby NA, Williams J, Kerr D, Gescher A and Chipman JK. The isoflavones equol and genistein do not
induce xenobiotic-metabolising enzymes in mouse and in human cells. Xenobiotica 27, 587-596
(1997)
Seymour, LW; Shoaibi, MA; Martin, A; Ahmal, A; Elvin, P; Kerr, DJ and Wakelam MJO Vascular
endothelial growth factors stimulates protein kinase C dependent phospholipase D activity in
endothelial cells. Lab.Invest. 75 3, 427-437 (1996)
Ferry, DR; Smith, A; Malkhandi, J; Fyfe, DW; de Takats, PG; Anderson, D; Baker, J; Kerr, DJ Phase I
trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.
Clinical Cancer Res 2: 659-668 (1996)
Eliopoulos AG, Dawson CW, Mosialos G, Floettmann J Eike, Rowe M, Armitage, RJ, Dawson J, Zapata
JM, Kerr DJ, Wakelam MJO, Reed JC, Kieff E and Young LS. CD40-induced growth inhibition in
epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common
mediator. Oncogene (1996) 13, 2243-2254 (1996)
Eliopoulos, AG; Kerr, DJ; Herod, J; Hodgkins, L; Krajewski, S; Reed, JC; Young, LS The control of
apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11: 12171228 (1995)
Eliopoulos, AG; Kerr, DJ; Maurer, HR; Hilgard, P; Spandidos, DA. Induction of the c-myc but not the
cH-ras promoter by platinum compounds. Biochem Pharmacol 50 1: 33-38 (1995)
Ferry, DR; Malkhandi, PJ; Russell, MA; Kerr, DJ. Allosteric regulation of [3H]vinblastine binding to Pglycoprotein of MCF-7 ADR cells by dexniguldipine. Biochem Pharmacol 49 12: 1851-1861(1995)
Cross, MJ; Stewart, A; Hodgkin, MN; Kerr, DJ; Wakelam, MJO. Wortmannin and its structural
analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in swiss 3T3 cells. J of
Biological Chem, 270 43: 25352-25355 (1995)
Liu, B; Anderson, D; Ferry, DR; Seymour, LW; de Takats, PG; Kerr, DJ.Determination of quercetin in
human plasma using reverse-phase high-performance liquid chromatography. J Chromatography
B, 666: 149-155 (1995)
Liu, B; Earl, HM; Poole, CJ; Dunn, J; Kerr, DJ Etoposide protein binding in cancer patients. Cancer
Chemother Pharmacol 36: 506-512 (1995)
Liu, B; Earl, HM; Baban, DF; Shoaibi, M; Fabra, A; Kerr, DJ; Seymour, LW Melanoma cell lines express
VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Comm 217
3: 721-727. (1995)
Ferry, DR; Kerr, DJ Multidrug resistance in cancer. Br Med J 308: 148-149 (1994)
32
Malkhandi, J; Ferry, DR; Boer, R; Gekeler, V; Ise, W; Kerr, DJ. Dexniguldipine-HCl is a potent
allosteric inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells. Eur J
Pharmacol Mol. Pharmacol. Section 288: 105-114 (1994)
Wishart GC; Bissett, D; Paul, J; Jodrell, D; Harnett, A; Habeshaw, T; Kerr, DJ; Macham, MA; Soukop,
M; Leonard, RCF, Knepil, J; Kaye, SB Quinidine as a resistance modulator of epirubicin in advanced
breast cancer: mature results of a placebo controlled randomized trial. J Clin Oncol 12 9: 17711777 (1994)
Cross, MJ; Stewart, A; Plumb, J; Mcauley, G; Hill, RA; Isaacs, N; Workman, P; Kerr, D; Wakelam, MJO
Inhibition of phospholipases and cell proliferation by demethoxyviridin. J Cellular Biochem. S18D:
56 (1994)
Kerr, DJ. Phase I clinical trials: adapting methodology to face new challenges. Annals Oncol 5 4:
S67-S70 (1994)
Morrison, JG; Bissett, D; Stephens, IFD; McKay, K; Brown, R; Graham, MA; Fichtinger-Schepman,AM;
Kerr, DJ. The isolation and identification of cis-diamminedichloroplatinum II-DNA adducts by anion
exchange HPLC and inductively coupled plasma mass spectrometry. Int J Oncology 2: 33-37
(1993)
Plumb, JA; Luo, W; Kerr, DJ. Effect of polyunsaturated fatty-acids on the drug sensitivity of human
tumour cell lines resistant to either cisplatin or doxorubicin. Br J Cancer 67 4: 728-733 (1993)
Kerr,DJ; Los,G. Ph armacokinetic principles of locoregional chemotherapy. Cancer Surveys 17: 105122 (1993)
Bissett, D; Setonoians, A; Cassidy, J; Graham, M; Chadwick, GA; Wilson, P; Auzanet, V; LeBail, N;
Kaye, SB; Kerr, DJ. Phase I and pharmacokinetic study of taxotere RP 56976 administered as a 24hour infusion. Cancer Res 53: 523-527 (1993)
Cassidy, J; Graham, MA; Huinink, WT; McDaniel, C; Setanoians, A; Rankin, EM; Kerr, DJ; Kaye, SB for
the EORTC ECTG. Phase I clinical study of LL-D49194a1 with retrospective pharmacokinetic
investigations in mice and humans. Cancer Chemother Pharmacol 31 5: 395-400 (1993)
Zoumpourlis, V; Kerr, DJ; Spandidos, DA. Differential Interaction of Cisplatin with the HIV-1 long
terminal repeat in a resistant ovarian carcinoma cell line. Anti-Cancer Drugs 4: 77-83 (1993)
Dunlop, DJ; Wright, EG; Lawrence, S; Graham, GJ; Holyoake, T; Kerr, DJ; Wolfe, SD; Pragnell, IB.
Demonstration of Stem cell inhibition and myeloprotective effects of SCI/rhMIPIa in vivo. Blood 79
9: 2221-2225. 1992
Bisset, D; Graham, MA; Setanoians, A; Chadwick, GA; Wilson, P; Koier, R; Henrar, R; Schwartsmann,
G; Cassidy, J; Kaye, SB; Kerr, DJ. Phase I and pharmacokinetic study of rhizoxin. Cancer Res 52:
2894-2898. 1992
Wade, JR; Kelman, AW; Kerr, DJ; Robert, J; Whiting, B Variability in the pharmacokinetics of
epirubicin : a population analysis. Cancer Chemother Pharmacol 29: 391-395. 1992
Zoumpourlis, V; Kerr, DJ; Spandidos, DA Carboplatin as opposed to cisplatin does not stimulate the
expression of the human immunodeficiency virus long terminal repeat sequences. Biochem
Pharmacol 43 3: 650-654. 1992
Bissett, D; Kaye, SB; Kerr, DJ. Can primary osteosarcoma act as a third space after high dose
methotrexate?. Eur J Cancer 27: 1060. 1992
33
Goldberg, JA; Willmott, N; Kerr, DJ; Sutherland, C; McArdle, CS. An in vivo assessment of adriamycinloaded albumin microspheres. Br J Cancer 65: 393-395. 1992
Scott, RN; Blackie, R; Kerr, DJ; Hughes, J; Burnside, G; MacKie, RM; Byrne, DS; McKay, AJ Melphalan
concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb
perfusion. Eur J Cancer 28a 11: 1811-1813. 1992
Scott, RN; Kerr, DJ; Blackie, R; Hughes, J; Burnside, G; MacKie, RM; Byrne, DS; McKay, AJ The
pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Br J
Cancer. 66: 159-166. 1992
Cassidy, J; Bissett, D; Kerr, DJ. Methodological aspects of phase I studies of novel anti-cancer agents
Review. Int J Oncol 1: 195-199. 1992
Graham, MA; Bissett, D; Setanoians, A; Kerr, DJ. Pre-clinical and phase I studies with rhizoxin to
apply a pharmacokinetically guided dose escalation scheme. J National Cancer Inst 84: 494-500.
1992
Bissett, D; Kerr, DJ; Cassidy, J; Meredith, P; Traugott, U; Kaye, SB Phase I and pharmacokinetic
study of D-verapamil and doxorubicin. Br J Cancer 64: 1168-1171. 1991
Eliopoulos, A; Kerr, DJ; Spandidos, DA. The effect of doxorubicin, daunorubicin and 4’-epidoxorubicin
on the exogenous c-myc promoter in mouse erythroleukaemia cells. Anticancer Res 11: 2153-2158.
1991
Graham, MA; Riley, RJ; Kerr, DJ. Drug metabolism in carcinogenesis and cancer chemotherapy.
Pharmac Ther 51: 275-289. 1991
Kaye, SB; Kerr, DJ. Multidrug resistance : Clinical relevance in haematological malignancies. Blood
Reviews 6: 39-42. 1991
Zoumpourlis, V; Kerr, DJ; Spandidos, DA. Doxorubicin stimulates transcription from the human
immunodeficiency virus long terminal repeat sequences. Cancer Letters 56: 181-185. 1991
Goldberg, JA; Kerr, DJ; Blackie, R; Whately, TL; Pettit, L; Kato, T; McArdle, CS.Mitomycin C-loaded
microcapsules in the treatment of colorectal liver metastases. Cancer 67: 952-955. 1991
Goldberg, JA; Murray, T; Kerr, DJ; Willmott, N; Bessent, RG, McKillop, JH; McArdle, CS.The use of
angiotensin II as a potential method of targeting cytotoxic microspheres in patients with intrahepatic
tumour. Br J Cancer 63: 308-310. 1991
Cytotoxic-loaded microspheres in patients with colorectal liver metastases.Br J Cancer 64: 114-119.
1991
Kerr, DJ; Kaye, SB.Chemoembolism in cancer chemotherapy. Critical Reviews in Therapeutic
Drug Carrier Systems 8 1: 19-37. 1991
Eliopoulos, A; Kerr, DJ; Spandidos, DA The effect of cisplatin and carboplatin on c-myc promoter in
erythroleukaemic cells. Anticancer Drugs 2: 597-601. 1991
Kerr, DJ; Plumb, JA; Freshney, RI; Khan, MZ; Spandidos, DA The effect of H-ras oncogene
transfection on response of mink lung epithelial cells to growth factors and cytotoxic drugs.
Anticancer Res 11: 1349-1352. 1991
Wishart, GC; Plumb, JA; Spandidos, DA; Kerr, DJ H-ras transfection in mink lung epithelial cells may
induce “atypical” multidrug resistance. Eur J Cancer 27 5: 673. 1991
34
Anderson, JH; Goldberg, JA; Eley, JG; Whateley, TL; Kerr, DJ; Cooke, TG; McArdle,CS A Phase I study
of regionally administered mitomycin microcapsules for patients with colorectal liver metastases.Eur J
Cancer 27 9: 1189-1190. 1991
Thomson, AM; Kerr, DJ; Steel, CM Transforming growth factor b1 is implicated in the failure of
Tamoxifen therapy in human breast cancer. Br J Cancer, 63: 609-614. 1991
Jones, RD; Kerr, DJ; Harnett, AN; Rankin, EM; Ray, S; Kaye, SB. A pilot study of quinidine and
epirubicin in the treatment of advanced breast cancer. Br J Cancer 62: 133-135. 1990
Kerr, DJ; Kaye, SB. Multidrug resistance in haematological malignancies. Haematology Reviews 4:
61-64. 1990
Kerr, DJ; Khan, MZ; Plumb, JA; Freshney, RI; Spandidos, DA. The effect of oncogene transfection on
epithelial cell response to cytotoxic drugs. Biochem Pharmacol 9: 375-379. 1990
Goldberg, JA; Kerr, DJ; Stewart, I; McArdle, CS. A comparison of regional and systemic chemotherapy
for hepatic metastases.Eur J Surg Oncol 16: 464-467. 1990
Goldberg, JA; Kerr, DJ; Willmott, N; McKillop, J; McArdle, CS. Regional chemotherapy for colorectal
liver metastases : a phase II evaluation of targeted hepatic arterial 5-fluorouracil for colorectal liver
metastases.Br J Surgery 77: 1238-1240. 1990
Carmichael, J; Cantwell, KA; Mannix, KA; Veale, D; Elford, HL; Blackie, R; Kerr, DJ; Kaye, SB; Harris,
AL.A phase I and pharmacokinetic study of didox admistered by 36 hour infusion. Br J Cancer 61:
447-450. 1990
Kerr, DJ; Slack, JA; Secrett, P; Stevens, MFG; Blackledge, GRP; Bradley, C; Kaye, SB. Relationships
between the pharmacokinetics and toxicity of mitozolamide. Cancer Chemother Pharmacol 25:
352-354. 1990
Kerr, DJ; Lewis, C; O'Neil, B; Lawson, N; Blackie, R; Newell, DR; Roball, F; Cox, J; Rankin, EM; Kay,
SB The myelotoxicity of carboplatin is influenced by the time of its administration. Haematol Oncol
8: 54-65. 1990
Goldberg, JA; Kerr, DJ; Watson, DG; Willmott, N; Bates, CD; McKillop, JH; McArdle, CS The
pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic
metastases.Br J Cancer 62: 78-85. 1990
Lewis, C; Lawson, N; Rankin, EM; Morrison, G; MacLean, AB; Cordiner, J; Cassidy, J; Kerr, DJ; Kaye,
SB Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian
cancer.Cancer Chemother Pharmacol 26: 283-287. 1990
Cummings, J; Double, JA; Bibby, M; Farmer, P; Evans, S; Kerr, DJ; Kaye, SB; Smyth, JF.
Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in
humans and mice. Cancer Res 49: 3587-3593. 1989
Kerr, DJ; Kaye, SB. Flavone acetic acid - preclinical and clinical activity. Eur J Cancer Clin Oncol 25
9: 1271-1272. 1989
Kerr, DJ; Pragnell, IB; Sproul, A; Cowan, S; Murray, T; George, D; Leake, R The cytostatic effects of
a-interferon may be mediated by transforming growth factor-b. J Molec Endocrin 2: 131-136. 1989
Kerr, DJ; Maughan, T; Newlands, E; Rustin, G; Bleehen, NM; Lewis, C; Kaye, SB. Phase II trials of
flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer 60: 104106. 1989
35
Kerr, DJ; Hynds, S; Shepherd, J; Packard, CJ; Kaye, SB. Comparative cellular uptake and cytotoxicity
of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell
monolayers. Biochem Pharmacol 37 20: 3981-3986. 1988
Kerr, DJ; Rogerson, A; Morrison, GJ; Florence, AT; Kaye, SB. Antitumour activity and
pharmacokinetics of niosome encapsulated adriamycin in monolayer, spheroid and xenograft. Br J
Cancer 58: 432-436. 1988
Kerr, DJ; Wheldon, TE; Hynds, S; Kaye, SB. Cytotoxic drug penetration studies in multicellular
tumour spheroids. Xenobiotica, 18 6: 641-648. 1988
Goldberg, JA; Fenner, J; Bradnam, MS; Bessent, RG; McKillop, JH; Kerr, DJ; McArdle, CS.Improved
tumour targeting of biodegradable microspheres with angiotensin II. Br J Surgery 75 12:1262. 1988
Goldberg, JA; Kerr, DJ; Willmott, N; McKillop, JH; McArdle, CS.Pharmacokinetics and
pharmacodynamics of locoregional 5 fluorouracil 5FU in advanced colorectal liver metastases.Br J
Cancer 57: 186-189. 1988
Kerr, DJ; Willmott, N; Levi, H; McArdle, CS.The pharmacokinetics and disposition of adriamycin loaded
albumin microspheres following intra renal arterial administration.Cancer 62: 878-882. 1988
McArdle, CS; Lewis, H; Hansell, D; Kerr, DJ; McKillop, J; Willmott, N.Cytotoxic loaded albumin
microspheres : a novel approach to regional chemotherapy.Br. J Surg 75: 132-134. 1988
Gouyette, A; Kerr, DJ; Kaye, SB; Setanoians, A; Cassidy, J; Bradley, C; Forrest, G; Soukop, M.
Flavone acetic acid : a non linear pharmacokinetic model. Cancer Chemother Pharmacol 22: 114119. 1988
Goldberg, JA; Kerr, DJ; Willmott, N; McArdle, CS; Murray, T; Hilditch, T Increased uptake of
radiolabelled microspheres with angiotensin II in colorectal hepatic metastases. Eur J Surgical
Oncol 14: 715. 1988
Kerr, DJ; Harding, M; Amarin, J; Farmer, J; Blackie, RG; Kaye, SB The pharmacokinetics of CHIP in
patients with impaired renal function and following intraperitoneal administration.Oncology and
Tumour Pharmacotherapy 5 3: 153-158. 1988
Veale, D; Carmichael, J; Cantwell, BMJ; Elford, HL; Blackie, R; Kerr, DJ; Kaye, SB; Harris, AL A phase
I and pharmacokinetic study of didox : A ribonucleotide reductase inhibitor. Br J Cancer 58: 70-72.
1988
Goldberg, JA; Fenner, J; Bessent, RG; Bradnam, MS; McKillop, JH; McKee, RF; McArdle, CS; Kerr,
DJ.Clinical evaluation of angiotensin II enhanced perfusion scintigraphy in metastatic liver disease.
Nuclear Med Comm 10: 557-566. 1988
Cummings,-J; Kerr,-D-J; Kaye,-S-B; Smyth,-J-F. Optimisation of a reversed-phase high-performance
liquid chromatographic method for the determination of flavone acetic acid and its major human
metabolites in plasma and urine. J-Chromatogr. 1988 Sep 23; 431(1): 77-85
Goldberg, JA; Bradnam, MS; Kerr, DJ; Haughton, DM; McKillop, JH;Bessent, RG; Willmott, N; McArdle,
CS; George, WD Arterio-venous shunting of microspheres in patients with colorectal liver metastases:
errors in assessment due to free pertechnetate and the effect of angiotensin II.Nuclear Med Comm
8: 1033-1046. 1987
Goldberg, JA; Bradnam, MS; Kerr, DJ; McKillop, JH; Bessent, RG; McArdle, CS; Willmott, N; George,
WD Single photon emission computed tomographic studies SPECT of hepatic arterial perfusion
scintigraphy HAPS in patients with colo- rectal liver metastases : improved targeting by tumour
microspheres with angiotensin II. Nuclear Med Comm 8: 1025-1032. 1987
36
Cummings, J; Willmott, N; More, I; Kerr, DJ; Lewi, HJ; McKillop, J. Comparitive cardiotoxicity and
antitumour activity of doxorubicin adriamycin and 4'-deoxydoxorubicin and the relationship to in vivo
disposition and metabolism in the target tissues. Biochemical Pharmacology 36 9: 1521-1526.
1987
Cummings, J; Kerr DJ; Kaye, SB. Occurrence of circulating 7-deoxyaglycone metabolites of 4'deoxydoxorubicin in man. Cancer Chemother Pharmacol 20: 263-264. 1987
Kerr, DJ; Kaye, SB; Cassidy, J; Bradley, C; Rankin, EM; Adams, L; Setonoians, A; Young, T; Forrest,
G; Soukop, M; Clavel, M. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res 47:
6776-6781. 1987
Cummings, J; Kerr, DJ; Kaye, SB Occurrence of circulating 7-deoxyaglycone metabolites of 4'deoxydoxorubicin in man. Cancer Chemother Pharmacol 20: 263-264. 1987
Cummings, J; Willmott, N; More, I; Kerr, DJ; Gilmour, J; Morrison, JG; Kaye, SB.Comparative
cardiotoxicity and antitumour activity of doxorubicin adriamycin and 4'-deoxydoxorubicin and the
relationship to in vivo disposition and metabolism in the target tissues.Biochem Pharmacol 36 9:
1521-1526. 1987
Kerr, DJ.Microparticulate vehicles as cytotoxic drug carriers. Cancer Drug Delivery 4 1: 55-60. 1987
Kerr, DJ; Kaye, SB.Aspects of cytotoxic drug penetration,
anthracyclines.Cancer Chemother Pharmacol 19: 1-5. 1987
with
particular
reference
to
Kerr, DJ; Kerr, AM; Wheldon, TE; Kaye, SB.In vitro chemosensitivity testing using the multicellular
tumour spheroid model. Cancer Drug Delivery 4 2: 124-130. 1987
Kerr, DJ; Wheldon, TE; Russell, JG; Maurer, HR; Florence, AT; Halbert, GW; Freshney, RI; Kaye,
SB.The effect of the non-ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer,
spheroid and clonogenic culture systems. Eur J Cancer Clin. Oncol. 23 9: 1315-1322. 1987
Kerr, DJ; Wheldon, TE; Kerr, AM; Freshney, RI; Kaye, SB. The effect of adriamycin and 4'deoxydoxorubicin on cell survival on human lung tumour cells grown in monolayer and as spheroids.
Br J Cancer, 54: 423-429. 1986
Kerr, DJ; Kaye, SB; Graham, J; Cassidy, J; Harding, M; Setanoians, A; McGrath, JC; Vezin, WR;
Cunningham, D; Forrest, G; Soukop, M. Phase I and pharmacokinetic study of LM985. Cancer Res
46: 3142-3246. 1986
Kerr, DJ; Graham, J; Cummings, J; Morrison, JG; Thompson, GG; Brodie, MJ; Kaye, SB The effect of
verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 18: 239-242.
1986
Kaye, SB; Cummings, J; Kerr, DJ. How much does liver disease affect the pharmacokinetics of
adriamycin? Eur J Cancer Clin Oncol 21 8: 893-895. 1985
Kerr, DJ; Graham, J; Blackie, RG; Cunningham, D; Kaye, SB. The relationship between steady-state
plasma levels of metoclopramide and control of cis-platinum induced emesis. Br J Pharmacol 20:
426-427. 1985
Kerr, DJ; Kerr, AM; Freshney, I; Kaye, SB. Comparative intracellular uptake of adriamycin and 4'deoxydoxorubicin by non-small cell lung tumor cells in culture and its relationship to cell survival.
Biochem Pharmacol 35 16: 2817-2823. 1985
Kaye,S.B; Cummings,J; Kerr,D.J. How much does liver disease affect the pharmacokinetics of
adriamycin? Eur.J.Cancer.Clin.Oncol. 1985 Aug; 21(8): 893-5
37
Section 3: Gene Therapy
Akita N, Maruta F, Seymour L, Kerr DJ, Parker AL, Asai T, Oku N, Nakayama J and Miyagawa S.
Identification of oligopeptides binding to peritoneal tumours of gastric cancer. Cancer Science. Vol
97 (1) 1075-1081. 2006
Palmer DH, Chen MJ, Searle PF, Kerr DJ, Young LS. Inhibition of NF-kappaB enhances the
cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy.
Gene Ther. 2005 Aug;12(15):1187-97.
Ming-Jen Chen, Nicola K. Green, Gary M. Reynolds, Joanne R. Flavell, Vivien Mautner, David J. Kerr,
Lawrence S. Young, Peter F. Searle. Enhanced efficacy of Escherichia coli nitroreductase/CB1954
prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene
Therapy. 1-11. 2004
Palmer, D H, Mautner V, Mirza D, Oliff S, Gerristen W, Van Der Sijp J R, Hubscher S, Reynolds G,
Bonney S, Rajaratnam R, Hull D, Horne M, Ellis J, Mountain A, Hill Simon, Harris PA, Searle PF, Young
LW, James ND and Kerr DJ. Virus-Directed Enzyme Prodrug Therapy: Intratumoural Administration
of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.
Journal of Clinical Oncology. 22: 1546-1552, 2004.
Chen MJ, Green NK, Reynolds GM, Flavell JR, Mautner V, Kerr DJ, Young LS, Searle PF.Enhanced
efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55Kdeleted oncolytic adenovirus vector. Gene Ther. 2004 Jul;11(14):1126-36.
Searle PF, Chen MJ, Hu L, Race PR, Lovering AL, Grove JI, Guise C, Jaberipour M, James ND, Mautner
V, Young LS, Kerr DJ, Mountain A, White SA, Hyde EI. Nitroreductase: a prodrug-activating enzyme
for cancer gene therapy. Clin Exp Pharmacol Physiol. 2004 Nov;31(11):811-6.
Palmer Green NK, Kerr DJ, Mautner V, Harris PA, Searle PF. The nitroreductase/CB1954 enzymeprodrug system Methods Mol Med. 2004;90:459-77
Green NK, McNeish IA, Doshi R, Searle PF, Kerr DJ, Young LS. Immune enhancement of
nitroreductase-induced cytotoxicity: Studies using a bicistronic adenovirus vector. Int J Cancer.
2003; 104(1): 104-12.
Palmer DH, Chen MJ, Kerr DJ. Taking Gene Therapy into the Clinic. Journal of Biomedicine and
Biotechnology. 2003; 71-77.
Kerr, DJ, Seymour, LW, & Maruta.
(2003) 3 (5): 779-788
Gene Therapy for colorectal cancer. Expert Opinion Biol.
Kerr DJ. Clinical development of gene therapy for colorectal cancer.
(2003) 3 615-622.
Nature Reviews Cancer,
Palmer D H, Milner A E, Kerr D J and Young L S. Mechanism of cell death induced by the novel
enzyme-prod
fluorouracil. British Journal of Cancer (September 2003), Volume 89, Number 5, Pages 944-950
Knox RJ, Burke PJ, Chen S and Kerr DJ. CB 1954: From the Walker Tumor to NQO2 and VDEPT.
Current Pharmaceutical Design, (2003), 9: 2091-2104
Palmer DH, Milner AE, Kerr DJ, Young LS. Mechanism of cell death induced by the novel enzymeprodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.
Br J Cancer. 2003 Sep 1;89(5):944-50.
38
Kerr DJ, Seymour LW, Maruta F. Gene therapy for colorectal cancer. Expert Opin Biol Ther. 2003
Aug;3(5):779-88.
Maruta F, Parker AL, Fisher KD, Murray PG, Kerr DJ, Seymour LW. Use of a phage display library to
identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of
human umbilical veins. J Drug Target. 2003 Jan;11(1):53-9.
Maruta,F; Parker,A.L; Fisher,K.D; Hallissey,M.T; Ismail,T; Rowlands,D.C; Chandler,L.A; Kerr,D.J;
Seymour,L.W. Identification of FGF receptor-binding peptides for cancer gene therapy. CancerGene-Ther. 2002 Jun; 9(6): 543-52
Palmer DH, Mautner V, Kerr DJ. Clinical experience with adenovirus in cancer therapy. Current
Opinion in Molecular Therapeutics. 4(5): 423-434 (2002).
Chen, M.J., Chung-Faye, G.A., Searle, P.F., Young, L.S., and Kerr, D.J. (2001). Gene Therapy for
colorectal cancer: therapeutic potential. BioDrugs 15, 357-67.
Chung-Faye, G., Palmer, D., Anderson, D., Baddeley, J., Hussain, S, Murray, P.I., Searle, P., Seymour,
L., Harris, P.A., Ferry, D., And Kerr, D.J. (2001). Virus-directed, enzyme prodrug therapy with
nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer
Res 7, 2662-8.
Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V, Searle PF*, Kerr DJ. In vivo
gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine
deaminase and uracil phosphoribosyltransferase.. Gene Ther 2001;8(20):1547-54
Djeha AH, Thomson TA, Leung H, Searle PF, Young LS, Kerr DJ. Combined adenovirus-mediated
nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid
tumors. Mol Ther 2001;3(2):233-40
Chung-Faye GA, Kerr DJ, Young LS, Searle PF. Gene therapy strategies for colon cancer. Mol Med
Today, 6: 82-7 (2000)
Djjeha, A.H., Hulme, A., Mountain, A., Young, L.S., Searle, P.F., Kerr, D.J., and Wrighton, C.M.
(2000). Expression E.coli B nitroreductase in established human tumor xenografts in mice results in
antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer
Gene Therapy 7, 721 –731.
Weedon,S.J; Green,N.K; McNeish,I.A; Gilligan,M.G; Mautner,V; Wrighton,C.J; Mountain, A; Young,L.S;
Kerr,D.J; Searle,P.F. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus
vector-mediated expression of E. coli nitroreductase. Int-J-Cancer. 2000 Jun 15; 86(6): 848-54
Green, N.K., Weedon, S.J., McNeish, I.A., Mautner, V., Young, L.S., Kerr, D.J., and Searle, P.F.
(1999). Gene Therapy for cancer: In vivo killing of tumour cells expressing E-coli nitroreductase
following administration of the prodrug CB1954. Gene Therapy 6, 33.
Murray, P.G.,Billingham, L.J., Hassan, H.T., Flavell, J.R., Nelson, P.N., Scott, K., Reynolds, G.,
Constandinou, C.M., Kerr, D.J., Devey, E.C., Crocker, J., and Young, L.S. (1999). Effect of EpsteinBarr virus infection on response to chemotherapy and survival in Hodgkin’s disease. Blood 94, 442447.
Grove JI, Searle PF, Weedon SJ, Green NK, McNeish IA, Kerr DJ. Virus-directed enzyme prodrug
therapy using CB1954. Anti-Cancer Drug Design, 14, 461-472 (1999)
39
Traunecker, H.C., Stevens, M.C.G., Kerr, D.J., and Ferry, D.R (1999). The acridonecarboxamide
GF120918 potently reverses P-glycoprotein – mediated resistancein human sarcoma MES-Dx5 cells.
British Journal of Cancer 81, 942-951.
Searle, P.F., Weedon, S.J., McNeish, I.A., Gilligan, M.G., Ford, M.J., Friedlos, F., Springer, C.J., Young,
L.S., and Kerr, D.J. Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954
following retroviral or adenoviral transfer of the E-coli nitroreductase gene. Advances in
Experimental Medicine and Biology 451, 107-113. (1998).
Gilligan MG, Knox P, Weedon S, Barton R, Kerr DJ, Searle P and Young LS. Adenoviral delivery of B71 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells. Gene
Therapy 5, 965-974 (1998)
Green NK, Gillian MG, Kerr DJ, Searle PF, Young LS. Gene therapy for cancer: prospects for the
treatment of lung tumours. Molecular Biology of the Lung, Vol. 2, No 10: 183-201 (1998)
McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, Kerr DJ, and Searle PF. Virus
directed enzyme prodrug therapy for ovarian and pancreatric cancer using retrovirally delivered E.
Coli nitroreductase and CB1954. Gene Therapy 1998; 5.1061-9.
McNeish IA, Gilligan MG, Green NK, Roberts SM, Kerr DJ, Friedlos F, Springer CJ, and Searle PF.
Virus-directed enzyme prodrug therapy using retrovirally delivered E. coli nitroreductase and CB1954.
British Journal of Cancer 1998; 78.155-6.
Herod, JJO; Eliopoulos, AG; Warwick, J; Niedobitek, G; Young, LS; Kerr, DJ. The prognostic
significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178-2184. (1996)
Thompson, AM; Steel, CM; Foster, ME; Kerr, D; Paterson, D; Deane, D; Hawkins, RA; Carter, DC;
Evans, HJ Gene expression in oestrogen-dependant human breast cancer xenograft tumours. Br J
Cancer 62: 78-84. 1990
40
General Medicine:
Kerr DJ and Midgley,R: Can we treat cancer for a dollar a day. New England Journal of Medicine,
363:801-803, 2010
Kerr DJ and Scott M. British Lessons on Health Care Reform. Perspective, New England Journal of
Medicine. 2009 Sep 24;361(13):e21.
Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea RW, Shepherd S, Stanley A, Sweeney
A, Ilde J Wheatley K, on behalf of the WARP Collaborative Group, Warfarin thromboprophylaxis in
cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet. Feb
2009, 373, 567-574.
Lingwood R, Boyle P, Milburn A, Ngoma T, Arbuthnott J, McCaffrey R, Kerr S and Kerr D. The
challenge of cancer control in Africa. Nature Reviews Cancer. 2008, Vol 8: 298-403
Mager, S R, Oomen MHA, Morente MM, Ratcliffe C, Knox K, Kerr DJ, Pezzella F, Riegman PHJ.
Standard operating procedure for the collection of fresh frozen tissue samples. European Journal
of Cancer. 43: 828-834, 2007.
Kerr F and Kerr DJ. Do we bear any moral responsibility to improving cancer care in Africa? Annals
of Oncology. 17: 1730-1731, 2006
Khayat D, Kerr DJ. Opinion: Science and Society:
Nature Reviews Cancer. 645-651, 2006.
A new model for cancer research in France.
Ref: Cowley AR, Davis J, Dilworth JR, Donnelly PS, Dobson R, Nightingale A, Peach JM, Shore B, Kerr
DJ, Seymour L. Fluorescence studies of the intra-cellular distribution of zinc bis (thiosemicarbazone)
complexes in human cancer cells. Chem Commun, 845-847, 2005.
Cowley A R., Davis J, Dilworth J, Donnelly P, Dobson R, Nightingale A, Peach J M., Shore B, Kerr D
and Seymour L. Contribution of academic research to discovery and development of medicines:
current status and future opportunities. European Journal of Pharmaceutical Sciences. 24: 245252. 2005. .
Boyle P, Ariyaratne M, Bartelink H, Baselga J, Berns A, Brawley OW, Burns H, Davidov M, Dinshaw
KA, Dresler C, Eggermont AM, Gajurel D, Gordina G, Gray N, Kakizoe T, Karki BS, Kasler M, Kerr DJ,
Khayat D, Kiselev A, Khuhaprema T, Klocker H, Levshin V, Martin-Moreno JM, McVie JG, Mendelsohn
J, Napalkov NP, Ngoma TA, Park JG, Philip T, Potschke-Langer M, Poudal HN, Rajan B, Ringborg U,
Rodger A, Seffrin JR, Shanta V, Shrestha MM, Thomas R, Tursz T, de Valeriola D, Veronesi U, Wiestler
OD, Zaridze D, Zatonski W, Zeng YX. Curbing tobacco's toll starts with the professionals: World No
Tobacco Day. Lancet. 2005 Jun 11-17;365(9476):1990-2
Couvreur P, Barguer D, Crommelin DJ, Duchene D, Engels JW, Kerr DJ, Krogsgaard-Larsen P, Meijer
DK, Paoletti R, Wagner E; EUFEPS. EUFEPS report. Contribution of academic research to discovery
and development of medicines: current status and future opportunities. Eur J Pharm Sci. 2005
Feb;24(2-3):245-52.
Knox K and Kerr DJ. Establishing a national tissue bank for surgically harvested cancer tissue.
British Journal of Surgery. 91: 134-136, 2004.
Kerr DJ and Ratcliffe C. Improving service delivery through an integrated approach to translational
cancer research. Eur Jour of Surgical Oncology. Vol 30, 61-63, 2004.
Kerr D J, Khayat D. The Entente Cordiale – natural and necessary. Annals of Oncology. 15: 1581,
2004
41
Kerr DJ. NTRAC pioneering a virtual model. The Lancet Oncology. 4:7: 393. 2003
Bevan H, Gowland B, Penny J, Berwich D, Kerr D. Redesigning Cancer Care. 2002. Brit Med
Journal. 324:164-166
Spurgeon, P., Barwell, F., and Kerr, D. (2000). Waiting times for cancer patients in England after
general practitioners’ referrals: retrospective national survey. British Medical Journal 320, 838839.
Kerr; D.J. A national cancer plan for the UK. Ann-Oncol. 2000 Dec; 11(12): 1511-2
Stone, P; Richardson,A; Ream,E; Smith,A.G; Kerr,D.J; Kearney,N. Cancer-related fatigue: inevitable,
unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann
Oncol. 2000 Aug; 11(8): 971-5
oung A, Kerr DJ. Genetic and immunological therapy for cancer. J R Soc. Med, 93: 10-14 (2000)
Kerr DJ. World summit against cancer for the new millennium the Charter of Paris.
Oncology, 11: 1-2 (2000)
Annals of
Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G,
Gudgeon A, Morgan M, Fornasiero A, Hoffman W, Michel J, Hatschek T, Tjabbes T, Chaudri HA,
Hornbergery U, Trunet PF. On behalf of the Letrozole International Trials Group. Letrozole, a new oral
aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect
and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Onc. 16, 2 :453-461
(1998).
Green S, Miles R, Kerr D. Improving delivery of cancer services – oncology site specialisation. Health
Trends, Vol 30, 3: 80-85 (1998)
Mackean MJ, Kerr D, Lesko M, Svedberg A, Hansson F, Jodrell D, Cassidy J. A feasibility study of
roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal
carcinoma. British Journal of Cancer, 78 (12): 1620-1623 (1998)
Kerr, DJ; Griffiths, R and Edwards B Delivering cancer care: a model for the West Midlands. Brit. J.
Cancer, 74: 667-669 (1996)
Hughes, MJ; Kerr, DJ; Cassidy, J; Soukop, M; McGregor, K; Blackburn, N; Yosef, H; Kaye, SB.A pilot
study of combination therapy with interferon-a-2a and 5-fluorouracil in metastatic carcinoid and
malignant endocrine pancreatic tumours. Annals of Oncology 7: 208-210 (1996)
Baban, DF; Murray, JA; Earl, HM; Kerr, DJ: Seymour, LW Quantitative analysis of vascular endothelial
growth factor expression in chronic lymphocytic leukaemia. Int J Oncol 8 1: 29-34 (1996)
Herod, JJO; Kerr, DJ, Luesley, DM. Mechanisms of resistance to platinum chemotherapeutic agents.
Contemp Rev Obstet Gynaecol 7: 25-28 (1995)
Miles, R; Kerr, DJ The Calman Report on Cancer Services. Current Obstetrics & Gynaecology 5 4
(1995)
De Takats, PG; Dunn, JA; Kerr, DJ; Morrison, JM Impact of adjuvant chemotherapy in breast cancer
on response to tamoxifen at relapse. Cancer Treat Rev 19b: 11-19. (1993)
42
Franchesci, S; Boyle, P; La Vecchia, C; Burt, AD; Kerr, DJ; MacFarlane, GJThe epidemiology of thyroid
cancer. Critical Reviews in Oncogenesis 41: 25-52 (1993)
Godden, J; Porteous, C; George, WD; Kerr, DJ.Bioassay of Transforming Growth factor-b activity in
acidic protein extracts from primary breast cancer specimens. Anticancer Res 13: 427-432 (1993)
Godden, J; Leake, R; Kerr, DJ. The response of breast cancer cells to steroid and peptide growth
factors. Anticancer Res. 12: 1683-1688. 1992
Kerr, DJ.Factors that make cancers grow. Science and Public Affairs: 31-36. 1992
Russell, J; Khan, MZ; Kerr, DJ; Spandidos, DA. The effect of transfection with the oncogenes H-ras, cmyc on the radiosensitivity of a mink epithelial cell line. Radiation Research 130: 113-116. 1992
Symonds, RP; Habeshaw, T; Kerr, DJ; Paul, J; Darling, A; Burnett, RA; Sotsiou, F; Linardopoulos, S;
Spandidos, DA. No correlation between ras, c-myc and c-jun proto-oncogene expression and
prognosis in advanced carcinoma of cervix. Eur J Cancer 28 10: 1615-1617. 1992
Smart, HE; Canney, P; Kaye, SB; Kerr, DJ. Myelofibrosis associated with seminoma. Clinical
Oncology 4: 132. 1992
Knowles, S; Smart, HE; Al-Dawoud, D; Kerr, DJ. Small bowel fistula secondary to endarteritis
obliterans complicating chemotherapy for small bowel lymphoma. Brit J Radiology 65: 349-350.
1992
Khan, MZ; Spandidos, DA; Kerr, DJ; McNichol, AM; Lang, JC; de Ridder, L; Freshney, RI. Oncogene
transfection of mink lung cells : effect on growth characteristics in vitro and in vivo. Anticancer Res.
11: 1343-1348. 1991
Bissett, D; Kunkeler, L; Zwanenburg, I; Paul, J; Gray, C; Swan, IRC; Kerr, DJ Long-term sequalae of
treatment for testicular germ cell tumours. Br J Cancer 62: 655-659. 1990
Leake, R; Kerr, D; Rinaldi, F Steroid hormones and growth factors in breast cancer. Annals NY Acad
Sci : 236-241. 1990
Cunningham, D; Bradlay, CJ; Forrest, GJ; Hutcheon, AW; Adams, L; Sneddon, M;Harding, M; Kerr,
DJ; Soukop, M; Kaye, SB. A randomised trial of oral nabilone and prochlorperazine compared to
intravenous metaclopramide and dexamethasone in the treatment of nausea and vomiting induced by
chemotherapy regimens containing cisplatin or cisplatin analogues.Eur J Cancer Clin Oncol 24 4:
685-689. 1988
Graham, J; Harding, M; Mill, L; Kerr, DJ; Rankin, E; Calman, KC; Kaye, SB Results of treatment of
non-seminomatous germ cell tumours : 122 consecutive cases in the West of Scotland 1981-1985.
Brit J Cancer 57 2: 182-185. 1988
James, G; Kerr, DJ; McLelland, A; Davies, DL. General peripheral nerve dysfunction in acromegaly: a
study by conventional and novel neurophysiological techniques. Neurology, Neurosurgery and
Psychiatry 50: 886-894. 1987
Kerr, DJ; Halberg, F; Sothern, R; Singh, VH; Alexander, WD. Chronobiologic quantification of thyroid
hormone rhythms. Chimioterapia XII: 526-528. 1987
Kerr, DJ; Singh, VK; Alexander, WD; Beastall, GH. The effect of low dose nocturnal dopamine infusion
on the circadian rhythm of TSH. Clinical Science 72: 737-741. 1987
Tumours of the diffuse endocrine system Kerr, DJ; Anderson, JR; Burt, AD.Europ J Surg Oncol 13:
189-195. 1987
43
Kerr, DJ; Burt, AD; Holloway, C; Beastall, G The effect of 5-fluorouracil on rat adrenal function.
Medical Oncology and Tumour Pharmaco-Therapy 3 2: 101-104. 1986
Kerr, DJ; Singh, VK; McConnell, N; Tsakiris, D; Junor, B. Thyroid function and dialysate hormone loss
in haemodialysis and chronic ambulatory peritoneal dialysis patients. Nephron 43: 164-169. 1986
Kerr, DJ; Burt, AD; Boyle, P; MacFarlane, GJ; Storer, AM; Brewin, TB. Prognostic factors in thyroid
cancer. Brit J Cancer 54: 475-482. 1986
Kerr, DJ; Singh, VK; Alexander, WD; Sothern, RB; Halberg, I. Chronobiologic quantification of
nocturnal low dose dopamine effect on circadian rhythms of thyroid related hormones and prolactin.
Chronobiologia Vol XIII 3: 245-248. 1986
Kerr, DJ; Burt, AB; Brewin, TB; Boyle, P. Divergence between mortality and incidence of thyroid
cancer.Lancet ii: 1932. 1985
Boyle, P; Burt, D; Kerr, DJ.The geographical pathology of thyroid cancer. Technical Report, 2692.
Dana Faber Cancer Institute, Harvard University. 1985
Kerr, DJ; McAlpine, I; Dagg, JH. Pseudohyperkalaemia. Lesson of the Week, British Medical
Journal, September, p890. 1985
Burt, AB; Kerr, DJ; Boyle, P; Brown, IL. Lymphoid and epithelial markers in small cell anaplastic
thyroid tumours. J.Clin.Pathol. 1985 Aug; 38(8): 893-6
Alexander, WD; Kerr, DJ; Ferguson, MM.First line test of thyroid function.Lancet ii: 647. 1984
Kerr, DJ; Alexander, WD.Is the TRH test usually unnecessary? Lancet ii: 1162. 1984
Kerr, DJ; Elliot, IIL; Hillis, WS Epileptiform seizures and electroencephalographic abnormalities as
manifestations of digoxin toxicity. Brit Med Journal 284: 162. 1982
44
PUBLISHED BOOK CHAPTERS
Midgley RS, Al-Salama H, Merrie A, Mortensen N and Kerr DJ. “Colorectal cancer: a multidisciplinary
approach”. Textbook of Clinical Gastroenterology and Hepatology. In Press. 2009
Midgley RS, Kerr DJ “Systemic adjuvant therapy of colon cancer” in
“Colorectal Cancer” Ed. Rougier Ph., Bleiberg H, Wilke HJ. Publ. Martin Dunitz Ltd UK. (1997)
Midgley RS, Kerr DJ (1998) “Adjuvant chemotherapy for colorectal cancer” in “Recent Advances in
Surgery” 21.Churchill Livingstone
"Chemoembolism in Cancer Therapy". D J Kerr and S B Kaye in Critical Reviews in Cancer, Ed. S
D Brack, p19-39, 8 1, 1991.
"Drug Metabolism and Cancer". M A Graham, R Riley and D J Kerr. Pharmac. Ther. Vol. 51, p275289, 1991. Ed. M J Brodie. Pergamon Press plc.
"The Effect of Angiotensin II on Tumour Blood Flow and the Delivery of Microparticulate Cytotoxic
Drugs". D J Kerr, J A Goldberg, J R Anderson, N Willmott, A T Whateley, C S McArdle and J McKillop.
Angiogenesis p339-345. Ed: R Steiner, PB Weisz and R Langer. Birkhauser Verby, 1992.
Graham, MA; Kerr, DJ; Workman, P.Absorption and distribution of anti-cancer drugs. In Florence
AT; Salole, EG eds. Pharmaceutical aspects of cancer chemotherapy. Oxford: ButterworthHeinemann Ltd, pp 1-26. (1993)
"The clinical evaluation of novel chemotherapeutic agents". Poole, CJ; Kerr, DJ in New Molecular
targets for cancer chemotherapy. Editors Kerr, Workman, P. CRC Press : 195-212, 1994.
"P-glycoprotein, a transporter with allosterically coupled drug-acceptor sites as a target for rational
drug design". Ferry, DR; Kerr, DJ in New molecular targets for chemotherapy. Editors: Kerr,
DJ; Workman, P. CRC Press, pp 177-193 (1994)
“Systemic Therapy of colorectal cancer” Midgley RS, Young AM, Ferry D, Kerr DJ, (2000) in
“Colorectal Cancer” Ed. McArdle C, Kerr DJ, Boyle P. Publ. ISIS Medical Media Ltd,UK.
“Principles of pharmacokinetics”. Gouyette, A; Kerr, DJ. In Peckham, Pinedo and Veronesi eds Oxford
Textbook of Oncology, Oxford Press, Vol 1, Sect 4.34: 852-864 (1995)
“New and miscellaneous anticancer drugs: future developments in drug design”. Kerr, DJ; Kaye, SB.
In Peckham, Pinedo & Veronesi eds. Oxford Textbook of Oncology 1.Oxford Press, pp 578-585
(1995)
"Principles Pharmacokinetique d'Agents Cytotoxique. A Gouyette and D J Kerr in
T.Tursz, Presse d’Or 1995.
Oncologie. Ed
"Gene-transfer therapy and pancreatic cancer". Searle,PF; Green, NK; Young, LS; Kerr, DJ;
Neoptolemos, JP. in Pancreatic Cancer; Molecular and clinical advances chapter 16: 214-223.
Editors: Neoptolemos, JP and Lemoine,NR. 1995
"Adjuvant chemotherapy and immunotherapy". DJ Kerr in Colorectal Cancer Chapter 10 pages
151-158. Ed: N S Williams. 1995
Morrison, J and Kerr D. Virus-directed suicide gene therapy. Cancer Therapy Molecular Targets in
Tumor-host Interactions. Editor: George F Weber. Chapter 16: 363-389. 2005
45
Nicum S, Midgley RS, Kerr DJ (2004) Chemotherapy and Radiotherapy for Colorectal Cancer. Recent
Advances in Coloproctology-Volume 2
Midgley RS, Merrie A, Mortensen N, Kerr DJ (2004) Multi-disciplinary Care of Colorectal Cancer. In
Gastroenterology and Hepatology: The Modern Clinicians Guide. Ed Weinstein W, Hawkey CJ and
Bosch J. Elsevier Science
Midgley RS (2002) “Systemic adjuvant therapy of colon cancer” in “Colorectal Cancer” Revised
edition. Ed. Rougier Ph., Kemeny N, Bleiberg H, Wilke HJ. Publ. Martin Dunitz Ltd UK
Midgley RS, Young AM, Ferry D, Kerr DJ, (2000) “Systemic Therapy of colorectal cancer” in
“Colorectal Cancer” Ed. McArdle C, Kerr DJ, Boyle P. Publ. ISIS Medical Media Ltd,UK.
Midgley RS, Kerr DJ (2000) Is adjuvant chemotherapy for colorectal cancer worthwhile? In:
Challenges in colorectal cancer. Ed Scholefield J. Publ. Blackwell Science,UK. Chapter 11:149-165
Midgley RS, Kerr DJ (1998) “Adjuvant chemotherapy for colorectal cancer” in “Recent Advances in
Surgery” 21.Churchill Livingstone
Midgley RS, Kerr DJ (1997) “Systemic adjuvant therapy of colon cancer” in “Colorectal Cancer” Ed.
Rougier Ph., Bleiberg H, Wilke HJ. Publ. Martin Dunitz Ltd UK.
"Advances in Cancer Research" D J Kerr. Chapter 16, p314-325 in Surgical Oncology. Ed. C S
McArdle. Publishers, Butterworth's Ltd.
"Adjuvant treatment of bowel cancer". DJ Kerr and RS Midgley, In: "Surgical Treatment of
Colorectal Cancer". Editor Mansell
Textbook of Clinical GI/Hepato. “Colorectal cancer: a multidisciplinary approach chapter”. Midgley
RS, Al-Salama HM, Merrie A, Mortensen N and Kerr D J. In press
46
EDITED BOOKS
"New Molecular Targets for Cancer Chemotherapy". Editors DJ Kerr, P Workman, CRC Press 1994.
"Regional Chemotherapy : Principles and Practice". Editors DJ Kerr, CS McArdle. Harwood Academic
Publishers 1998.
"Clinical Textbook of colorectal Cancer". Editors DJ Kerr, CS McARdle and P. Boyle. ISIS Academic
Publishers 2000.
"ABC of Colorectal Cancer", British Medical Journal Book Series, Editors DJ Kerr, AM Young and R
Hobbs, 2001.
“Anticancer Therapeutic Development: from laboratory bench to bedside” – Editors B Baguley and D
J Kerr, 2001
“Advances in Colorectal Cancer” Eds Kerr DJ, Bodmer WF, McArdle CS and Pignatelli M. British Medical
Bulletin, 64, 2002, Oxford University Press
“Cancer biotherapy an introductory guide”. Eds, Young, Rowett, Kerr. Oxford University Press. 2006.
“Gastrointestinal Oncology: Evidence and Analysis”.
Healthcare. 2007
Eds, McCulloch, Karpeh, Kerr, Ajani. Informa
“Textbook of Gastrointestinal Cancer”. Eds, Jankowski, Kerr, Fong, Blackwells Publishing. 2008
“Oncology Drugs Handbook”, Oxford University Press, in preparation
“Oxford Textbook of Oncology”, Oxford University Press, in preparation
JOURNAL EDITORIAL BOARDS
 Annals of Oncology – Editor in Chief (1998 – 2006)
 Nature Clinical Cancer Reviews
 Japanese Journal of Clinical Oncology
 Seminars in Oncology
 Molecular Oncology
 Chinese Clinical Oncology
47